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INTRODUCTION- MICROPARTICLES 
 
Oral drug administration is by far the most preferable route for taking 
medications. However, their short circulating half life and restricted absorption via a 
defined segment of intestine limits the therapeutic potential of many drugs. Such a 
pharmacokinetic limitation leads in many cases to frequent dosing of medication to 
achieve therapeutic effect. This results in pill burden and consequently, patient 
complains. Rational approach to enhance bioavailability and improve 
pharmacokinetic and pharmacodynamic profile is to release the drug in a controlled 
manner and site specific manner.   
Microparticles are a type of drug delivery systems where the particle size 
ranges from one micron (one thousandth of a mm) to few mm. This 
microencapsulation technology allows protection of drug from the environment, 
stabilization of sensitive drug substances, elimination of incompatibilities, or masking 
of unpleasant taste. Hence, they play an important role as drug delivery systems 
aiming at improved bioavailability of conventional drugs and minimizing side 
effects1.  
Microparticulate drug delivery system is one of the processes to provide the 
sustained & controlled delivery of drug to long periods of time. They are small 
particles of solids or small droplets of liquids surrounded by walls of natural & 
synthetic polymer films of varying thickness & degree of permeability acting as a 
release rate controlling substance & have a diameter upto the range of 0.1µm-200µm2 
. 
Advantages of Microparticles: 
Recently, controlled release has become a very useful tool in pharmaceutical 
area, offering a wide range of actual and perceived advantages to the chronic diseases 
such as rheumatoid arthritis, osteoarthritis, and musculoskeletal disorders including 
degenerative joint conditions still demand long-term therapy. With the advent of 
microparticles following advantages were noted in the dosage forms 
(1) Effective delivery of agents which re insoluble or sparingly soluble in water. 
(2) They give the products which exhibit immediate release properties & can give 
80% or more of active agent in about 10 minutes or less. Ex. Nimesulide. 
(3) The technique provides the way for improving taste of an active agent. 
(4) They increased the relative bioavailability of drugs. 
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(5) The formulation of microparticles also provides the method of targeting the drug 
delivery to specific sites. 
(6) The microparticles hold great potential in reducing the dosage frequency & 
toxicity of various drugs. 
(7) Microparticles in the form of microcapsules can also be used as carrier for drugs 
& vaccines as diagnostic agents & in surgical procedures. 
(8) They can also be used to produce amorphous drugs with desirable physical 
properties. 
(9) They also caused the reduction of the local side effects ex. GI irritation etc of 
drugs on oral ingestion. 
(10) They provide the sustained release formulation with lower dose of drug to 
maintain plasma concentration & improved patient compliance. 
(11) The PH triggered microparticles are used in immunization, transfection & gene 
therapy. 
(12) Parentral microparticles have the advantage of administering high concentration 
of water 
soluble drugs without severe osmotic effects at the site of administration. 
(13) They also have an advantage of being stored in dry particle or suspension form 
with little or no loss of activity over an extended storage period. 
(14) They are useful in administration of effervescent dosage form of medicaments to 
individual unable to chew. Ex. Debilitated patients having difficulty in swallowing 
solids & the elderly. 
(15) In contrast, smaller microparticles need to be prepared for application to other 
sites such as the eye, lung, and joints 2. 
Disadvantages  
Although the advantages of microparticles are impressive there are certain 
limitations. These include:  
1. The costs of the materials and processing of the controlled release preparation, 
which may be substantially higher than those of standard formulations.  
2. The fate of polymer matrix and its effect on the environment.  
3. The fate of polymer additives such as plasticizers, stabilizers, antioxidants and 
fillers. 
4. Reproducibility is less. 
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5. Process conditions like change in temperature, pH, solvent addition, and 
evaporation/agitation may influence the stability of core particles to been capsulated. 
6. The environmental impact of the degradation products of the polymer matrix 
produced in  
hydrolysis, oxidation, solar radiation or biological response to heat, agents and the 
cost, time probability of success in securing government registration of the product, if 
required3. 
 
Polymer & other substances used in microparticle preparation 
Wall Materials 
The coating material can be selected from a wide variety of natural and 
synthetic polymers depending on the core material to be encapsulated and the desired 
characteristics. The amount of coating material used ranges from 3% to 30% of the 
total weight, which corresponds to a dry film thickness of less than 1–200 μm, 
depending on the surface to be coated4. 
1. Natural or synthetic hydrophilic colloids  
These are large molecules that are soluble or dispersible in aqueous solutions. 
Here the capsule wall presents a good barrier to oily and hydrophobic materials, but it 
is usually a poor barrier to hydrophilic substances. Hydrophobic colloids are realized 
in encapsulating water-soluble drugs.  Soluble starch & its derivatives including 
Amylodextrin, Amylopectin & Carboxy methyl starch is used as wall forming 
material in solid microsphere preparation. Some examples of natural and synthetic 
hydrophilic colloids  are agar acrylic, polymers, polyacrylic acid, poly acryl 
methacrylate, gelatin, poly(lactic acid), pectin(poly glycolic acid), waxes (poly 
hydroxyl butyrate-co-valerate), cellulose derivatives, cellulose acetate phthalate, 
Nitrate, Ethyl cellulose, Hydroxy ethyl cellulose, Hydroxypropylcellulose, Hydroxy 
propyl methyl cellulose, Hydroxypropylmethylcellulose phthalate, Methyl cellulose, 
Sodium carboxymethylcellulose, Poly(orthoesters), Polyurethanes, Poly(ethylene 
glycol), Poly(ethylene vinyl acetate), Polydimethylsiloxane, Poly(vinyl acetate 
phthalate), Polyvinyl alcohol, Polyvinyl pyrrollidone, shellac5.  
2. Biocompatible polymer 
It includes poly (lactic) acid (PLA), poly (glycolic acid) (PLGA). PLGA is a 
water-insoluble polymer; strength, hydrophobicity, and pliability are the significant 
physical advantages. As a polymeric vehicle, biocompability, biodegradability, 
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predictability of degradation, ease of fabrication, and regulatory approval are features 
that make PLGA desirable for medical applications. Natural polymers Albumin Chitin 
Starch, Collagen Chitosan Dextrin, Gelatin, Hyaluronic acid, Dextran, Fibrinogen, 
Alginic acid ,Casein, Fibrin, Poly(ortho esters). Polyalkylcyanoacrylate, 
Polyanhydrides. 
The bioavailability enhancers used are lysophatide, lysophosphatidyl choline. 
Permeability modifier & membrane fluidity modifier used include enamines like 
phenyl alanine enamine. Malonates like diethylene ox methylene malonate, 
salicylates, bile salts, fusidates etc5. 
 
3. Biodegradable polymer 
          Advances in polymer science have opened up possibilities for using a wide 
variety of polymeric materials as drug delivery systems. Biodegradable polymers, by 
virtue of their ability to degrade in the body naturally, offer enormous advantages 
over conventional drug delivery systems. It eliminated the need for surgery and also 
does not elicit any adverse reactions from the body. Polymeric drug delivery systems 
are mainly intended to deliver the drug over a period of time. Some of the materials 
that are currently being used/studied for controlled drug delivery include poly (methyl 
methacrylate), poly (vinyl alcohol), polyacrylamide, polyethylene glycol, polylactic 
acid, polyglycolic acid, polylacticglycolic acid, and polyanhydrides . Most 
biodegradable polymers are designed to degrade as a result of hydrolysis of the 
polymer chains into biologically acceptable and progressively smaller compounds. 
For example in the case of polylactic glycolic acid, the polymer would eventually 
break down into lactic and glycolic acid, enter the Krebs cycle and further broken 
down into carbon dioxide and water. Drugs formulated in polymeric devices are 
released either by diffusion through the polymeric barrier, or by erosion of the 
polymer material, or by a combination of both diffusion and erosion mechanisms. A 
wide variety of natural and synthetic biodegradable polymers have been investigated 
for drugtargeting or prolonged drug release. Amongst them, the thermoplastic 
aliphatic poly (esters) like PLA, PGA, and especially PLGA have generated 
tremendous interest due to their excellent biocompatibility and biodegradability. The 
wide acceptance of the lactide/glycolide polymers as suture materials, made them an 
attractive candidate for biomedical applications like ligament reconstruction, tracheal 
replacement, surgicaldressings, vascular grafts, nerve, dental, and fracture repair. The 
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first work on parenteral controlled release of drugs using PLA was reported by Wise 
and Beck. Since then various polymeric devices like microspheres, microcapsules, 
nanoparticles, pellets, implants and films have been fabricated using these polymers 
for the delivery of a varietyof drug classes. Also they are easy to formulate into drug 
carrying devices for variety of applications, such as, orthopedic drug delivery; they 
have been approved by the FDA for drug delivery use6.  
Techniques of microparticle preparation: 
When preparing controlled release microspheres, the choice of the optimal 
method has utmost importance for the efficient entrapment of the active substance. 
Various pharmaceutically acceptable techniques for the preparation of microparticles 
have been given. Some of the methods include: 
1. Emulsion–solvent evaporation (o/w, w/o, w/o/w). 
2. Phase separation (non solvent addition and solvent partitioning). 
3. Interfacial polymerization. 
4. Spray drying. 
5. Emulsion extraction process. 
6. Jet milling technique. 
7. Fluidization & solvent precipitation method. 
1. Emulsion-solvent evaporation 
The solvent evaporation method involves the emulsification of an organic 
solvent (usually methylene chloride) containing dissolved polymer and 
dissolved/dispersed drug in an excess amount of aqueous continuous phase, with the 
aid of an agitator. The concentration of the emulsifier present in the aqueous phase 
affects the particle size and shape. When the desired emulsion droplet size is formed, 
the stirring rate is reduced and evaporation of the organic solvent is realized under 
atmospheric or reduced pressure at an appropriate temperature. Subsequent 
evaporation of the dispersed phase solvent yields solid polymeric microparticles 
entrapping the drug.  
The solid microparticles are recovered from the suspension by filtration, 
centrifugation, or lyophilization solvent such as acetonitrile, are emulsified into an 
immiscible lipophilic phase, with light mineral oil commonly being used, in the 
presence of an oil-soluble surfactant such as Span. However, an important drawback 
of using an oil external phase is cleaning up the final product. The oil has to be 
removed using organic solvents such as n-hexane. Diphenyl hydramine 
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hydrochloride, mitomycin C, adriamycin, cephradine and cefadroxil6. Phenobarbitone 
and timolol maleate are some examples of drugs that have been encapsulated by this 
procedure.  
The concentration of the emulsifier present in the aqueous phase affects the 
particle size and shape. When the desired emulsion droplet size is formed, the stirring 
rate is reduced and evaporation of the organic solvent is realized under atmospheric or 
reduced pressure at an appropriate temperature. Subsequent evaporation of the 
dispersed phase solvent yields solid Polymeric microparticles entrapping the drug. 
The solid microparticles are recovered from the suspension filtration, centrifugation, 
or lyophilization6. 
Single-Emulsion Solvent Evaporation: 
i. O/W Emulsion Solvent Evaporation Technique 
For emulsion solvent evaporation, there are basically two systems from which 
to choose: oil-in-water (o/w) or water-in-oil (w/o). Oil-in- water emulsion was to 
encapsulate progesterone. Afterward lipid-soluble drugs such as steroids, local 
anesthetics, bleomycin sulfate, doxorubicin, chlorpromazine, naltrexone and 
promethazine were encapsulated successfully.  
In general, solvent evaporation method is particularly suitable for the 
microencapsulation of lipophilic drugs that can be either dispersed or dissolved in the 
dispersed phase of a volatile solvent. Sansdrap and Moes suggested that in order to 
obtain batches of microspheres with reproducible sizes, manufacturing factors such as 
emulsifier concentration, stirring rate and organic phase volume should be under 
control7. 
ii. Oil-in-Oil Emulsification–Solvent Evaporation Technique 
Oil-in-oil (sometimes referred as water-in oil) emulsification process was 
developed for the encapsulation of highly water soluble drugs7. In this technique, 
polymer and drug, contained in a polar solvent such as acetonitrile, are emulsified into 
an solvent such as acetonitrile, are emulsified into an immiscible lipophilic phase, 
with light mineral oil commonly being used, in the presence of an oil-soluble 
surfactant such as Span. However, an important drawback of using an oil external 
phase is cleaning up the final product.  
The oil has to be removed using organic solvents such as n-hexane. Diphenyl 
hydramine hydrochloride, mitomycinC, adriamycin, cephradine and cefadroxil, 
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phenobarbitone and timolol maleate are some examples of drugs that have been 
encapsulated by this procedure. 
iii. Multiple-Emulsion Technique (w/o/w) 
Multiple-emulsion or double-emulsion technique is appropriate for the 
efficient incorporation of water soluble peptides, proteins, and other macromolecules. 
This method allows the encapsulation of water-soluble drugs with an external aqueous 
phase when compared to nonaqueous methods as the o/o solvent evaporation or 
organic phase separation. In brief, the polymers are dissolved in an organic solvent 
and emulsified into an aqueous drug solution to form a w/o emulsion. This primary 
emulsion is re-emulsified into an aqueous solution containing an emulsifier to 
produce multiple w/o/w dispersion.  
The organic phase acts as a barrier between the two aqueous compartments, 
preventing the diffusion of the active material toward the external aqueous phase. 
Microspheres manufactured by the (w/o/w method exhibit various morphologies such 
as porous or nonporous external polymer shell layers enclosing hollow, macro porous, 
or micro porous internal structures, depending on different parameters. 
2. Phase Separation/Coacervation: 
The term coacervation was suggested for the first time by two Dutch 
scientists. The word coacervation comes from the latinacervus, meaning aggregation, 
and the prefix co, signifying the preceding union of the colloidal particles. In this 
process, both the drug and the polymer should be insoluble in water, while a water-
immiscible solvent is required for the polymer. 
Coacervation/phase separation can be obtained by temperature change, 
nonsolvent or salt addition, incompatible polymer addition, and polymer–polymer 
interaction. Drugs belonging to different pharmacological groups have been 
encapsulated. Antibiotics, Anti-inflammatory agents, analgesics, and antihypertensive 
are some of these groups7. 
Description of Coacervation/Phase Separation Methods: 
This method is divided into two main groups: aqueous and organic. Aqueous 
phase separation has been subdivided by Bungenberg de Jong and Kruyt as complex 
and simple coacervation. 
i. Simple coacervation 
Simple coacervation can be accomplished by the addition of chemical 
compounds with a high affinity for water, such as salts and alcohols. In principle, 
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simple coacervation can be brought about in any aqueous polymer solution when 
temperature, pH, solvent, and salt are properly chosen. 
This process depends primarily on the degree of hydration produced. The 
added substances cause two phases to be formed, one rich in colloid droplets and the 
other poor. Its principal requirement is the creation of an insufficiency of water in a 
part of the total system. Figure illustrates the preparation of microcapsules by simple 
Coacervation.  
The microencapsulation process can be explained by the following steps. 
 
a. Dispersion of the core material in an aqueous solution of the polymer. 
b. Creation of insufficiency of water for the hydrophilic colloid and the 
deposition of the coacervate around the core. 
c. Gelation of the coacervate and hardening of the microcapsules. 
ii. Complex coacervation 
This technique of complex coacervation was first described by Phares and 
Sperandio. It involves neutralization of the charges on the colloids and depends 
primarily on pH. This is accomplished by mixing two colloids of opposite charges 
together. The encapsulation process in complex coacervation consists of four steps: 
a. Preparation of a hydrophilic colloid solution. 
b. Addition of a second hydrophilic colloid solution of opposite charge to induce 
coacervation. 
c. Deposition around the core. 
d. Gelation of the coacervate and hardening of the microcapsules 7. 
Organic Phase Separation Methods 
Organic phase separation is the inverse of the aqueous phase separation 
process in that the wall-containing phase is hydrophobic in nature and the core 
material is water miscible. The principle is to enclose water-soluble material with a 
polymeric wall material in an organic solvent by adding a nonsolvent or a second 
polymeric material to induce phase separation8. 
3. Interfacial Polymerization Method 
Interfacial polymerization technique is one in which two monomers, one oil-
soluble and the other water-soluble, are employed and a polymer is formed on the 
droplet surface. The method involve the reaction of mono meric units located at the 
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interface existing between a core material substance & a continuous phase in which 
the core material is dispersed8. 
4. Spray drying 
Spray drying is used to protect sensitive substances from oxidation based on 
the atomization of a solution by compressed air and drying across a current of warm 
air. Microparticle formulation by spray drying is conducted by dispersing a core 
material in a coating solution, in which the coating substance is dissolved & in which 
the core material is insoluble, & then by atomizing the mixture into an air stream. The 
heated air causes removal of solvent from the coating solution thus causing formation 
of the microcapsule8. 
5, Emulsion extraction process 
             This method which is used to prepare microparticles, involves organic phase 
removal by extraction of the organic solvent. The method involves external phase 
miscible organic solvent such as mixing acetonitril and dichloromethane; organic 
phase is removed by extraction with liquid paraffin. The rate of solvent removal by 
extraction method depends on the temperature of external phase, ratio of emulsion 
volume to the mineral oil and the solubility profile of the polymer Several methods 
and techniques are potentially useful for the preparation of Microparticles in the ﬁeld 
of controlled drug delivery. The type and the size of the microparticles, the 
entrapment, release characteristics and stability of drug in microparticles in the 
formulations are dependent on the method used. One of the most common methods of 
preparing microparticles is the single emulsion technique. Poorly soluble, lipophilic 
drugs are successfully retained within the microparticles prepared by this method. 
However, the encapsulation of highly water soluble compounds including protein and 
peptides presents formidable challenges to the researchers. The successful 
encapsulation of such compounds requires high drug loading in the microparticles, 
prevention of protein and peptide degradation by the encapsulation method involved 
and predictable release, both rate and extent, of the drug compound from the 
microparticles. The above mentioned problems can be overcome by using the double 
emulsion technique, alternatively called as multiple emulsion technique. Aiming to 
achieve this various techniques have been examined to prepare stable formulations 
utilizing w/o/w, s/o/w, w/o/o, and s/o/o type double emulsion methods. This article 
reviews the current state of the art in double emulsion based technologies for the 
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preparation of microparticles including the investigation of various classes of 
substances that are pharmaceutically and biopharmaceutically active8. 
6, Jet milling technique  
            An innovative technique for solvent free preparation of microparticles is 
described. Microparticles were prepared by a melt grinding technique which consists 
of three consecutive steps of melting in case of placebo microparticles or co-melting 
of polymer and drug in case of drug loaded microparticles, respectively, and 
pregrinding. In a final jet milling step the reduction of the particle size and 
smoothening of the microparticle surface occurred. Different polymers of PLA and 
PLGA type were utilised. The influence of the preparation parameters during the 
process were investigated according to microparticle properties like particle size 
distribution, habitus or surface morphology by executing a 2 factorial design. The 
minimum mean particle size distribution (x50 value) reached 4–6 μm. Scanning 
electron microscopy revealed that non-porous microparticles with a smooth surface 
were prepared. The release pattern of estrioltriacetate loaded microparticles of 
Resomer® R 202H nearly followed a zero order release kinetic over a period of 21 
days without an initial burst effect. The preparation process can be carried out in a 
reproducible manner. The results demonstrate that microparticle preparation is 
possible by the following unique melt grinding technique without using organic 
solvents9. 
7. Fluidization & solvent precipitation method 
                
                There are three commonly used fluid-bed process: top, tangential and 
bottom spray methods. When the granules are coated by the top-spray granulator 
system, granules usually have a porous surface and an interstitialvoid space, therefore, 
the bulk density of produced granules is usually lower than that attainable by 
granulation techniques. A rotating-disk method (tangential-spray coating method), 
which combinescentrifugal, high-density mixing and the efficiency of fluid bed 
drying, yields a product that has higher bulk density but still has some interstitial void 
space. It yields particle that are less friable and more spherical in shape. the solid core 
particle are fluidized by air pressure and a solution of wall materials is sprayed on to 
the particles from the bottom of the fluidization chamber parallel to the air stream. At 
the spraying nozzle is immersed in the airflow and sprays the coating 
materialsconcurrently into the fluidized particles, the coating solution droplets travel 
INTRODUCTION 
11 
only a short distance before contacting the solid particles. As a result the film is 
applied more evenly and the coated film is more homogenous. The coated particles 
are lifted on the air stream, which dries the coating as the particles are carried away 
from the nozzle. The particlesrise on the air stream, the settle down, and then begin 
another cycle. The cycles until the desired film thickness are achieved. It is well 
suited for uniform coating of particle with a polymeric membrane in a single 
operation9. 
Gelatin Dispersion 
This is a specific embodiment of a more general approach in which the 
polymer filaments or monomer subunits used in forming the microparticles are mixed 
with a suspension of proteins, such as agar, gelatin, or albumin. One method employs 
alginate plus Ca +2 in producing the particles. The mixture is then dispersed under 
conditions effective to produce desired sized particles containing the mixture 
components. In the case of gelatin containing particles, the mixture may be cooled 
during the dispersion process to produce gelled particles having a desired size. The 
particles are then treated under polymerization and/or cross linking conditions, 
preferably under conditions that do not also lead to cross linking of gelatin molecules 
to the polymer structure. After microparticle formation, the gelatin molecules may be 
removed from the structure, with such in a decondensed form, e.g., by heating the 
material or enzymatic digestion8.  
Superficial antisolvent precipitation technique 
This technique is useful if the drug is insoluble in gas & gas is soluble in 
liquid. The drug is dissolved in polymeric solution of suitable solvent. Then the 
application of an antisolvent decreases the solubility of material the dissolved in 
solution leading to microparticle beads formation.  
pH-triggered microparticle - Microparticles that are designed to release their 
payload when exposed to acidic conditions are provided as a vehicle for drug 
delivery9. Any therapeutic, diagnostic or prophylactic agent may be encapsulated in a 
lipid-protein-sugar or polymer matrix with a pH- triggering agent to form 
microparticles. Preferably the diameter of the pH triggered microparticles ranges from 
50 nm to 10 µm. The matrix of the particles may be prepared using any known lipid 
(e.g., DPPC), protein (e.g., albumin), or sugar (e.g., lactose). 
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The matrix of the particles may also be prepared using any synthetic polymers 
such as polyesters. The process of formulation include providing an agent & 
contacting with a pH triggering agent & component selected from lipid, proteins, 
sugars & spray drying the resultant mixture to create microparticles. Typically, the pH 
triggering agent is a chemical compound including polymers with a pKa less than 7. 
pH triggering agent used is poly (butyl methacrylateco-(2-dimethyl amino ethyl) 
methacrylate-co-methyl methacrylate) (1:2:1) i.e. Eudragit 110.  
The pH triggered microparticles release the encapsulated agent when exposed 
to an acidic environment such as in phagosome or endosome of a cell that has taken 
up particles thereby allowing for efficient delivery of agent intracellularly9. 
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Condensed phase microparticles 
They are an alternative method for storing & administration of drugs at high 
concentration in condensed phase with sizes ranging between 0.05-50 microns. They 
consists of 
1. Matrix of cross linked polyionic polymer filaments capable of swelling from a 
condensed phase to an expanded, decondensed phase or state, when the matrix is 
exposed to monovalent counter ions. 
2. Small molecules entrapped in microparticle matrix, with such in its condensed 
phase.  
3. Polyvalent counter ions effective to retard the release of small molecules from the 
micro particles, when exposed to monovalent counter ions.  
The composition is useful in delivery of vehicle for reagents is unstable on 
storage, or where it is desirable to introduce reagent at a selected step in reaction The 
method of preparation include infusing the compound into polymer suspended in a 
decondensed phase typically containing 10-200 millimole concentration of 
monovalent counter ions leading to hydration & increase in size. After compound 
infusion into open particle matrices, multivalent counter ion mainly Calcium ion is 
added to fully condense the microparticle. This technique is used for small, water 
soluble drug molecules. They are having advantages that high concentration of water 
soluble rugs can be administered without severe osmotic effect at site of 
administration thus they are essentially nonosmotic until they decompose & release 
drug10. 
Evaluation of Microparticles 
The various evaluation techniques for microparticle preparation are as follows: 
1. Particle shape & size determination 
 It can be done by microscopy, sieve analysis, laser light scattering, coulter counter 
method, photon correlation spectroscopy. 
a. Crystallinity can be evaluated by differential scanning calorimetery analysis. 
b. Shape & surface morphology can be studied by freeze fracture microscopy & 
freezes etch. electron microscopy. 
c. Laser diffractometer & light microscope is also used to measure the size range 
of the microparticles. 
d. Size analysis of all the batches of prepared microparticles can be carried out 
using a set of standard sieves ranging from 10-100 meshes. The microparticles 
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are passed through the set of sieves and the amount retained on each sieve is 
weighed. The arithmetic average diameter is determined by dividing the total 
weight size by 1009-10. 
2. Bulk and Tap density 
             Aerated bulk density is when the volume of the particle is at a maximum, 
caused by aeration, just prior to complete breakup of the bulk. The amount to which 
the particles collapse and fill voids between the particles depends on some powder 
properties, including particle shape, interparticle friction, and cohesion. 
Tapped density 
            Tapped bulk density is, the maximum bulk density that can be achieved 
without deformation of the particles. In practice, it is generally unrealistic to attain 
this theoretical tapped bulk density, and a lower value obtained after tapping the 
particle in a standard manner is used11-12. 
3. The Thermal Properties 
The Thermal Properties are detected by Differential Scanning Calorimetry 
(DSC), Thermo gravimetric analysis. 
Differential Scanning Calorimetry (DSC) 
In DSC the amount of heat required to increase the temperature of a sample 
and reference is measured as a function of temperature. Both the sample and reference 
are maintained at nearly the same temperature throughout the experiment. Generally, 
the temperature program for a DSC analysis is designed such that the sample holder 
temperature increases linearly as a function of time. The reference sample should 
have a well-defined heat capacity over the range of temperatures to be scanned.  
Thermogravimetric analysis or thermal gravimetric analysis (TGA)  
It is a type of testing that is performed on samples to determine changes in 
weight in relation to change in temperature. Analysis is carried out by raising the 
temperature gradually and plotting weight (percentage) against temperature. The 
temperature in many testing methods routinely reaches 1000°C or greater, but the 
oven is so greatly insulated that an operator would not be aware of any change in 
temperature even if standing directly in front of the device. After the data are 
obtained, curve smoothing and other operations may be done such as to find the exact 
points of inflection11. 
4. Electrostatic interaction is detected by rheological & FTIR assays (Fourier 
Transform Infra red spectroscopy) using potassium bromide pellets. 
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5. Peptide entrapment & entrapment efficacy can be evaluated by HPLC. 
6. The Drug release studies was evaluated by USP method II or dissolution test 
method using phosphate buffer PH 6.8 with the temperature of release medium at 
37°C ±0.5 & then assaying spectophotometrically11-12. 
7. Release kinetics to model the dissolution profile from the microparticles system 
two different mathematical differential equation can be used i.e., (1) first order 
equation; (2) Higuchi's square root of time equation. 
1, First order model can be expressed as 
Mt / M = 1- e- k1 t  
2, Higuchi's square root of time model is given by  
Mt / M = kH t1/2 
Where Mt is the amount of drug released at time t, M is the maximal amount of drug 
released at infinite time, k1 and kH are the rate constants for first order and Higuchi 
model, respectively. 
Stability studies were evaluated to find out stable product under storage. Micro 
particles can be stored in Blass bottles at elevated temperature i.e. 4±1ºC freezing 
temperature, 25±1ºC room temperature, & 50±1ºC hot temperature for a period of 30 
days & observed for change in drug content & morphology12-13. 
Applications of microparticles 
1. Application areas of microcapsules include pharmaceutical and biotechnology 
products, cosmetics, diagnostic aids, biological filtration devices, veterinary 
and zoo technical products, foods and food additives, flavors, fragrances, 
detergents, paints, agricultural chemicals, adhesives, industrial chemicals, 
household products, packaging, textiles, photographic and graphic arts 
materials.  
2. These microcapsules are important in providing sustained and controlled 
release, improving drug stability, reducing vaporization of volatile oils, 
protecting moisture/light/oxidation–sensitive drugs, masking unpleasant taste 
and odor, converting liquids to powders, and separating incompatible 
substances within a single system. 
3. Amoxicillin, ampicillin, bacampicillin, cephalexin, cephradine, 
chloramphenicol, clarithromycin, eryithromycin, potassium pheneticillin, 
ofloxacin, and ciprofloxacin are some examples of the encapsulated 
antibiotics. 
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4. Anti-inflammatory drugs are another group in which microencapsulation is 
employed. Diclofenac sodium, flufenamic acid, glaphenine, hydrocortisone, 
ibuprofen, indomethacin, naproxen, oxyphenbutasone, and prednisone are 
examples of encapsulated drugs in this group. 
5. Sulfadiazine, sulfamethizole, sulfamethoxazole, sulfamerazine, and 
sulfisoxazole are some representatives of sulfa drugs that are encapsulated.  
6. Furosemide, chlorothiazide, and sulfonamide were encapsulated in order to 
prepare sustained release formulations that would offer the advantage of 
avoiding short periods of peak diuresis observed with the conventional 
formulations.  
7. Isosorbide-5-mononitrate (IS-5-MN), dihydralazine sulfate, piretanide and 
propranolol HCl, captopril, nicardipin, and dipyridamole are examples of 
microencapsulated antihypertensives. IS-5-MN microcapsules were optimized 
and formulate to sustain the action and to overcome the tolerance developed in 
conventional preparations.  
8. Vitamins A, B1, B2, B6, B12, C, D, were encapsulated to provide formation 
of smooth- and thick-walled microcapsules largely prevented the aggregation 
of microcapsules and showed low dissolution rate. 
9. Converting Liquids to Free-Flowing Powders Citrus essential oil, cod liver oil, 
benzaldehyde, carbon tetrachloride, and oil droplets were coated and 
recovered as fine powders. The authors have stated that the bulk droplet size 
of the encapsulated material appeared to be a factor in the strong capsule wall, 
which protects against vaporization and oxidation.  
10. Air filled micro particles are used in echocardiography & other ultrasonic 
imaging techniques. They are also used as opacifier or reflectivity enhancers 
in cosmetics12. 
11. Solid microspheres are of particulars used in nasal delivery of drugs including 
polypeptides, insulin, somatostain, metolopromide etc.  
12. PH triggered micro particles have been used to deliver drugs by various means 
ex-by IV inject, intra dermal injection, rectally, orally, intra vaginally, 
inhalationally, mursoual delivery etc. 
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13. They are also used for administering. An antigenic epitote of a pathogen or a 
tumor. 
14. The micro particles are useful in transficting cells & gene therapy.  
15. Condensed phase micro particles are used as stable strong kit for enzymes, 
antibodies, dye13. 
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LITERATURE REVIEW 
Nagendra R et al13., prepared and evaluated microparticles containing Oxybutynin 
Chloride for controlled release using HPMC and Ethyl cellulose by solvent 
evaporation method using different ratios of drug to polymer and prepared 
microparticles were characterized. The method is simple, rapid and economical and 
does not imply the use of toxic organic solvents. The method used was suitable for 
both water-soluble and insoluble drugs. The Drug to polymer blend ratio of 2.5:10:5 
(F5) produced discrete spherical microparticles. The DSC thermogram obtained for 
the pure drug and formulation shows no significant shift in the endothermic peaks 
confirming the stability of the drug in the formulation. From the results of drug 
content determination, it can be inferred that there was a proper and uniform 
distribution of drug in the micro particles. The in vitro drug release data showed the 
release of a drug in a controlled manner. 
SHAYEDA et al14., studied on formulation and evaluation of floating microparticles 
of metoprolol succinate. They concluded floating multiunit drug delivery system was 
successfully prepared by non-aqueous emulsion solvent evaporation method for a 
freely water soluble drug, Metoprolol succinate by using Eudragit RLPO and RSPO, 
Eudragit S 100. The formulation containing drug to Eudragit RSPO in 1:6 ratio could 
sustain the release for 8 hours. However, further pharmacokinetic studies are needed 
to understand and confirm the effective absorption of Metoprolol succinate from 
floating microparticles. Further, the microspheres can also be compressed into 
tablets, filled into capsules, or formulated into oral suspension for reconstitution. 
Mitra Jelvehgar et al15; done formulation and evaluation of in-vitro characterization 
of gastic-mucoadhesive microparticles/discs containing antidiabetic drug like 
metformin hydrochloride (MH) for oral administration with a view of combination of 
two polymers  Carbomer 934p (cp)   and  Ethylcellulose (EC). They concluded that 
in their study % entrapment efficiency was higher for F2microparticles than other 
formulations. While practical yield obtained was higher for (1:3) F2 microparticles. 
The particle size analysis revealed that all formulations gave particles in the range of 
794.33-1071. 52μm which is suitable for oral administration of formulation. Increase 
in the mucoadhesive polymer led to increase in mucoadhesion and degree of 
swelling. However, Carbopol showed higher mucoadhesion and swelling degree than 
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EC. As the concentration of mucoadhesive polymer increased, the drug releases also 
decreased proportionally, because it produced hydrogel on the mucus. From all the 
parameters studied, it can be concluded that microparticles and discs do not have 
significant difference together (p > 0.05). MH microparticles are better gastric-
adhesive delivery system for the formulation of MH for gastro-intestinal 
administration. Thus, the formulated microspheres seem to be a potential candidate 
as oral controlled drug delivery system for diabetes therapy. 
KPR Chowdary et al16., Prepared and Evaluated of Gliclazide Micro particulate 
Drug Delivery Systems Employing Starch Acetateper. They conculded Gliclazide 
release from the starch acetate micro particles was slow and spread over longer 
periods of time. The drug release depended on the proportion of core: coat in the 
micro particles. A good linear relationship (R²=0.826) between percent coat and 
release rate (ko)was observed. The relationship could be expressed by the linear 
equation, y=12.18-0.173x where x is percentcoat and y is release rate (ko). Gliclazide 
release from the starch acetate micro particles was by non fickian (anomalous) 
diffusion. Formulation F2 prepared using a Core: coat ratio of 8:2 gave slow, 
controlled and complete release (100%) of Gliclazide over 12hours. As such 
formulation F2 is considered as a promising micro particulate DDS for oral control 
release of Gliclazide over 12 hours for b.i.d administration. 
Josephine Lenojenita et al17., performed on formulation and evaluation of 
microparticles containing curcumin for colorectal cancer. The micro particles 
prepared were filled in hard gelatin capsules which were enteric coated with 
cellulose acetate phthalate (CAP) which prevent the burst effect of capsule in acidic 
pH of stomach. The in vitro release study showed that there was no drug release in 
pH 1.2 acidic buffer, drug release was between 66.12% - 71.87% for 10 hrs in 
phosphate buffer and controlled by Fickian diffusion mechanism. They concluded 
from their investigation that Eudragit microspheres are promising controlled release 
carriers for colon-targeted delivery of curcumin. 
Dv Gowda et al18., prepared and evaluated ranolazine (RNZ) microparticle with 
mixture of eudragit (EU) and ethylcellulose (EC) by the phase separation method for 
controlled release. Spherical discrete microparticles were obtained and it exhibited 
good micromeritic properties. From the results of the particle size analysis it was 
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clear that all the process variables were within the limits and the process is 
reproducible. FT-IR studies indicated that there was no interaction between the drug 
and the polymers in the prepared microparticles. The DSC thermograms obtained 
from the pure drug and the formulation showed no significant shift in the 
endothermic peaks confirming the stability of the drug in the formulation. The in 
vitro drug release studies showed that the release of the drug was found to be 
diffusion-controlled. Results of dissolution studies for formulation (3:1) F5 and the 
marketed product showed that both have nearly similar release profiles. From their 
results, they concluded that the microparticles formulation is easy to administer, 
simple and economical with increased patient compliance. Hence RNZ could be 
formulated into microparticles as a controlled drug release dosage form by the phase 
separation method. These results demonstrate the potential use of EU and EC 
combinations for fabrication of delivery systems of other water soluble drugs in a 
controlled manner. 
Pai Rohan V et al19., developed and evaluated chitosan microparticles based dry 
powder inhalation formulations of rifampicin and rifabutin. They conculded Both 
rifampicin and rifabutin-loaded microparticles had MMAD close to 5 μm and FPF 
values of 21.46% and 29.97%, respectively. In vitro release study in simulated lung 
fluid pH 7.4 showed sustained release for 12 hours for rifampicin microparticles and 
up to 96 hours for rifabutin microparticles, the release being dependent on both 
swelling of the polymer and solubility of the drugs in the dissolution medium. In 
vitro uptake studies in U937 human macrophage cell line suggested that 
microparticles were internalized within the macrophages. In vivo acute toxicity study 
of the microparticles in Sprague Dawley rats revealed no significant evidence for 
local adverse effects. Both rifampicin and rifabutin-loaded microparticles had 
MMAD close to 5 μm and FPF values of 21.46% and 29.97%, respectively. In vitro 
release study in simulated lung fluid pH 7.4 showed sustained release for 12 hours 
for rifampicin microparticles and up to 96 hours for rifabutin microparticles, the 
release being dependent on both swelling of the polymer and solubility of the drugs 
in the dissolution medium. In vitro uptake studies in U937 human macrophage cell 
line suggested that microparticles were internalized within the macrophages. In vivo 
acute toxicity study of the microparticles in Sprague Dawley rats revealed no 
significant evidence for local adverse effects. Thus, spray-dried microparticles of the 
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anti-tubercular drugs, rifampicin and rifabutin, could prove to be an improved, 
targeted, and efficient system for treatment of tuberculosis.  
BALAGANI. PAVAN KUMAR et al20., formulated and evaluated glimepiride 
loaded cellulose acetate microparticles by using an emulsion solvent evaporation 
technique.They coculded The resulting microparticles obtained by solvent 
evaporation method were free flowing in nature. The mean particle size of 
microparticlesranges from 145.26 – 187.42 µm and encapsulation efficiency ranges 
from 90.38 – 96.00%. The infrared spectra and differential scanningcalorimetry 
thermographs confirmed the stable character of Glimepiride in the drug-loaded 
microparticles. Scanning electron microscopy revealedthat the microparticles were 
spherical in nature. In vitro release studies revealed that the drug release was 
sustained up to 12 hrs. The releasekinetics of Glimepiride from optimized 
formulation followed zero-order and peppas mechanism. The mechanism of drug 
release from the microparticles was found to be non-Fickian type.  Which will not 
only sustain the release of drug but also manage complicacy of the diabetes in a 
better manner.  
ZhiYong Qian et al21., prepared alginate coated chitosan microparticles for vaccine 
delivery. They concluded that their prepared alginate coated chitosan microparticles, 
with mean diameter of about 1µm, was suitable for oral mucosal vaccine. Moreover, 
alginate coating onto the surface of chitosan microparticles could modulate the 
release behavior of (Bovine Serum Albumin) BSA from alginate coated chitosan 
microparticles and could effectively protect model protein (BSA) from degradation 
in acidic medium in vitro for at least 2 h. In all, the prepared alginate coated chitosan 
microparticles might be an effective vehicle for oral administration of antigens. 
Maja Simonoska Crcarevska et al22., Done a chitosan coated ca–alginate 
microparticles loaded with budesonide for delivery to the inflamed colonic mucosa. 
They concluded Using a novel one-step spray-drying process uncoated and 
Eudragit S 100 coated chitosan–Ca–alginate microparticles efficiently loaded with 
budesonide (BDS), with bioadhesive and controlled release properties in GIT, were 
prepared. Microparticles were spherical with mean particle size of 4.05–5.36 μm, 
narrow unimodal distribution and positive surface charge. A greater extent of 
calcium chloride limited the swelling ratio of beads, while swelling behaviour of 
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coated beads was mainly determined by properties of enteric coating. Comparing the 
release profiles of formulations, under different pH conditions, influence of polymer 
properties and concentration of cross-linker on the rate and extent of drug release 
was evident. Coating has successfully sustained release of BDS in buffers at pH 2.0 
and 6.8, while providing potential for efficient release of BDS at pH 7.4. Release 
data kinetics indicated influence of erosion and biodegradation of polymer matrix on 
drug release from microparticles. Prepared formulations were stable for 12 months 
period at controlled ambient conditions. that coated microparticles prepared by one-
step spray-drying procedure could be suitable candidates for oral delivery of BDS 
with controlled release properties for local treatment of inflammatory bowel diseases.  
Nahla S Barakat and Alanood S Almurshedi et al23.,  designed and developed 
gliclazide loaded chitosan microparticles for oral sustained drug delivery: 
invitro/invivo evaluation. They concluded Gliclazide release from the starch acetate 
micro particles was slow and spread over longer periods of time. The drug release 
depended on the proportion of core: coat in the micro particles. A good linear 
relationship (R²=0.826) between percent coat and release rate (ko)was observed. The 
relationship could be expressed by the linear equation, y=12.18-0.173x where x is 
percentcoat and y is release rate (ko). Gliclazide release from the starch acetate micro 
particles was by non fickian (anomalous) diffusion. Formulation F2 prepared using a 
Core: coat ratio of 8:2 gave slow, controlled and complete release (100%) of 
Gliclazide over 12hours. As such formulation F2 is considered as a promising micro 
particulate DDS for oral control release of Gliclazide over 12 hours for b.i.d 
administration. from their results, they suggests that gliclazide–chitosan 
microparticles are a valuable system for the sustained delivery of gliclazide.  
Ahmed S. Zidan. et al24., Formulated anastrozole microparticles as biodegradable 
anticancer drug carriers. They concluded The purpose of this study was to develop 
poly(d,1-lactic-coglycolic acid) (PLGA)-based anastrozole microparticles for 
treatment of breast cancer. An emulsion/extraction method was used to prepare 
anastrozole sustained-release PLGA-based biodegradable microspheres. Gas 
chromatography with mass spectroscopy detection was used for the quantitation of 
the drug throughout the studies. Microparticles were formulated and characterized in 
terms of encapsulation efficiency, particle size distribution, surface morphology, and 
drug release profile. Preparative variables such as concentrations of stabilizer, drug-
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polymer ratio polymer viscosity, stirring rate, and ratio of internal to external phases 
were found to be important factors for the preparation of anastrozole-loaded PLGA 
microparticles. Fourier transform infrared with attenuated total reflectance (FTIR-
ATR) analysis and differential scanning calorimetry (DSC) were employed to 
determine any interactions between drug and polymer. An attempt was made to fit 
the data to various dissolution kinetics models for multiparticulate systems, including 
the zero order, first order, square root of time kinetics, and biphasic models. The 
FTIR-ATR studies revealed no chemical interaction between the drug and the 
polymer. DSC results indicated that the anastrozole trapped in the microspheres 
existed in an amorphous or disordered-crystalline status in the polymer matrix. The 
highest correlation coefficients were obtained for the Higuchi model, suggesting a 
diffusion mechanism for the drug release  from their results, anastrozole 
microparticles with PLGA could be an alternative delivery method for the long-term 
treatment of breast cancer.  
Hombreiro Perez M, et al25.,  done a preparation and evaluation of poly(ϵ-
caprolactone) microparticles containing both a lipophilic and a hydrophilic drug. 
They concluded that In vitro release studies revealed a controlled release of 
nifedipine and propranolol HCl from microparticles prepared by the o/w-method; a 
burst release of propranolol HCl was observed from microparticles prepared by the 
w/o/w-method. In conclusion, microparticles containing both a hydrophilic and a 
Lipophilic drug were successfully prepared.  
Sakchai Wittaya-areekul et al26., studied on preparation and in vitro evaluation of 
mucoadhesive properties of alginate/chitosan microparticles containing prednisolone. 
They conclued that, prednisolone release at a pH of 6.8 after 4 h was between 63 and 
79% for the particles prepared by the one-step method and between 57 and 88% for 
the particles prepared by the two-step method with a prednisolone drug load of 5 and 
10% (w/v), respectively. Their results showed that depending on the preparation 
method these chitosan coated alginate particles show different mucoadhesiveness 
whereas their other properties are not statistically significant different. 
Manmohan Singh et al27., prepared a cationic microparticles: A potent delivery 
system for DNA vaccines. They concluded that, the microparticles released intact 
and functional DNA over 2 weeks in vitro. In addition, the microparticles induced 
higher levels of marker gene expression in vivo. After intra muscular immunization, 
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the microparticles induced significantly enhanced serum antibody responses in 
comparison to naked DNA. Moreover, the level of antibodies induced by the 
microparticles was significantly enhanced by the addition of a vaccine adjuvant, 
aluminum phosphate. In addition, in contrast to naked DNA, the cationic 
microparticles induced potent cytotoxic T lymphocyte responses at a low dose. 
Philip F.Builders et al28., studied on preparation and evaluation of mucinated 
sodium alginate microparticles for oral delivery of insulin. The microparticles 
formed were generally multi-particulate, discrete and free flowing. The prepared  
microparticles were filled into hard gelatin capsules and the in vitro insulin release as 
well as the blood glucose reduction after oral administration to diabetic rabbits were 
determined. Before insulin loading, microparticles were round and smooth, 
becoming fluffier, less spherical and larger with rough and pitted surface after insulin 
loading. The insulin content of the microparticles increased with increase in their 
sodium alginate content. The various insulin-loaded microparticles prepared with the 
mucinated sodium alginate when encapsulated exhibited lag time before insulin 
release. The time taken to reach maximum insulin release from the various 
formulations varied with the mucin–sodium alginate ratio mix. The mean dissolution 
time of insulin from the microparticles prepared with sodium alginate, mucin, 
sodium alginate: mucin ratios of 1:1, 3:1 and 1:3 was 11.21 ± 0.75, 3.3 ± 0.42, 
6.69 ± 023, 8.52 ± 0.95 and 3.48 ± 0.65 (min.), respectively. The percentage blood 
glucose reduction for the subcutaneously administered insulin was significantly 
(p < 0.001) higher than for the formulations. The blood glucose reduction effect 
produced by the orally administered insulin-loaded microparticles prepared with 
three parts of sodium alginate and one part of mucin after 5 h was, however, equal to 
that produced by the subcutaneously administered insulin solution, an indication that 
it is an effective alternative for the delivery of insulin.  
Jianhua Zheng et al29., perfomed on preparation and evaluation of 
floating‐bioadhesive microparticles containing clarithromycin for the eradication of 
Helicobacter pylori. They concluded that in vitro buoyancy and drug‐release testing 
confirmed the good floating and sustained‐release properties of (chitosan- alginate- 
ethylcellulose ) CAEMs. About 74% of the CAEMs floated in an acetate buffer 
solution for 8 h, and 90% of the clarithromycin contained in the CAEMs was 
released within 8 h in a sustained manner. In vivo mucoadhesive testing showed that 
LITERATURE REVIEW 
25 
61% of the CAEMs could be retained in the stomach for 4 h. Under a pretreatment 
with omeprazole, the clarithromycin concentration in gastric mucosa of the CAEM 
group was higher than that of the clarithromycin solution group. These results 
suggest that CAEMs might be a promising drug delivery system for the treatment 
of H. pylori infection.   
Mvan der Lubben et al30., performed on Chitosan microparticles for oral 
vaccination: preparation, characterization and preliminary in vivo uptake studies in 
murine Peyer's patches. They concluded that these results were verified using field 
emission scanning electron microscopy, which demonstrated the porous structure of 
the chitosan microparticles, thus facilitating the entrapment of ovalbumin in the 
microparticles. Loading studies of the chitosan microparticles with the model 
compound ovalbumin resulted in loading capacities of about 40%. Subsequent 
release studies showed only a very low release of ovalbumin within 4 h and most of 
the ovalbumin (about 90%) remained entrapped in the microparticles. Because the 
prepared chitosan microparticles are biodegradable, this entrapped ovalbumin will be 
released after intracellular digestion in the Peyer's patches. Initial in vivo studies 
demonstrated that fluorescently labeled chitosan microparticles can be taken up by 
the epithelium of the murine Peyer's patches. Since uptake by Peyer's patches is an 
essential step in oral vaccination, these results show that the presently developed 
porous chitosan microparticles are a very promising vaccine delivery system.  
 
Mcuna M.J and Alonso D Torres et al31., performed on Preparation and in vivo 
evaluation of mucoadhesive microparticles containing amoxycillin–resin complexes 
for drug delivery to the gastric mucosa. They conculded, microparticles consisting of 
amoxycillin-loaded ion-exchange resin encapsulated in mucoadhesive polymers 
(polycarbophil and Carbopol 934) were prepared with the aim of increasing the 
efficacy of amoxycillin in the treatment of peptic ulcers by achieving targeted 
delivery to the gastric mucosa and prolonged drug release. An oil-in-oil solvent 
evaporation technique was conveniently modified in order to obtain polymer 
microparticles containing multiple amoxycillin–resin cores. Polycarbophil 
microparticles were spherical, Carbopol 934 microparticles irregular. In vitro release 
of amoxycillin was rapid with or without a polymer coating. Gastrointestinal transit 
in rats was investigated by fluorescence microscopy using particles loaded with 
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fluorescein instead of amoxycillin: gastric residence time was longer, and the 
distribution of the particles on the mucosa apparently better, without any polymer 
coating. 
J.AKo et al32.,  prepared a chitosan microparticles with tripolyphosphate (TPP) by 
ionic crosslinkingand done a characterization intended for controlled drug delivery. 
They concluded the particle sizes of TPP-chitosan microparticles were in range from 
500 to 710 μm and encapsulation efficiencies of drug were more than 90%. The 
morphologies of TPP-chitosan microparticles were examined with scanning electron 
microscopy. As pH of TPP solution decreased and molecular weight (MW) of 
chitosan increased, microparticles had more spherical shape and smooth surface. 
Release behaviors of felodipine as a model drug were affected by various preparation 
processes. Chitosan microparticles prepared with lower pH or higher concentration 
of TPP solution resulted in slower felodipine release from microparticles. With 
decreasing MW and concentration of chitosan solution, release behavior was 
increased. The release of drug from TPP-chitosan microparticles decreased when 
cross-linking time increased. These results indicate that TPP-chitosan microparticles 
may become a potential delivery system to control the release of drug. 
 
R.P.Raffin et al33., perfomed on Preparation, characterization, and in vivo anti-ulcer 
evaluation of pantoprazole-loaded microparticles.They conculded Pantoprazole is an 
important drug in the treatment of acid-related disorders. This work concerns the 
preparation and characterization of gastro-resistant pantoprazole-loaded 
microparticles prepared using an O/O emulsification/solvent evaporation technique. 
The in vivo activity of the pantoprazole-loaded Eudragit S100 microparticles was 
carried out in rats. Furthermore, tablets containing the microparticles were also 
investigated. Microparticles presented spherical and smooth morphologies (SEM) 
and they remained intact in the inner surface of tablets. DSC and IR analyses showed 
that pantoprazole was physically and molecularly dispersed in the polymer. In vivo 
anti-ulcer evaluation showed that the microparticles were able to protect rat stomachs 
against ulcer formation, while the drug aqueous solution did not present activity. 
Drug dissolution profiles from tablets demonstrated slower release than untabletted 
microparticles. Weibull equation was the best model for describing the drug release 
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profiles from microparticles and tablets. As regards the acid protection, tablets 
showed a satisfactory drug protection in acid medium (61.05 ± 8.09% after 30 min).  
Herbert Hoyeret et al34., performed on Preparation and evaluation of microparticles 
from thiolated polymers via air jet milling. They conculded Microparticles from 
(thiolated) chitosan had a positive charge whereas microparticles from (thiolated) 
poly(acrylic acid) were negatively charged. The maximum protein load for 
microparticles based on chitosan, chitosan–glutathione (Ch–GSH), poly(acrylic acid) 
(PAA) and for poly(acrylic acid)–glutathione (PAA–GSH) was 7 ± 1%, 11 ± 2%, 
4 ± 0.2% and 7 ± 2%, respectively. The release profile of all microparticles followed 
a first order release kinetic. Chitosan (0.5 mg), Ch–GSH, PAA and PAA–GSH 
particles showed a 31.4-, 13.8-, 54.2- and a 42.2-fold increase in weight, 
respectively. No significant cytotoxicity could be found. Thiolated microparticles 
prepared by jet milling technique were shown to be stable and to have controlled 
drug release characteristics. After further optimizations the preparation method 
described here might be a useful tool for the production of protein loaded drug 
delivery systems.  
NahedHegazy et al35., peformed on Preparation and in vitro evaluation of 
pyridostigmine bromide microparticles.They conculded Pyridostigmine bromide 
(PB) is an anticholinesterase agent whose aqueous solubility is high and which has a 
short elimination half-life. Its dosage rate in the treatment of myastenia gravis is 
frequent due to the short half-life and it exhibits side effects. Microparticles designed 
to deliver a pharmaceutical active ingredient efficiently at the minimum dose and 
also to enhance stability, reduce side effects and modify drug release were prepared 
in this study using an acrylic polymer (Eudragit) as the vehicle by the spray-drying 
technique. The drug was either dissolved or dispersed in the polymeric solution and 
following the preparation of microparticles using different ratios of ingredients, 
characterization studies including the determination of shape, particle size 
distribution, amount loaded, release and stability of PB were performed. The results 
obtained were compared to those of pure PB. Drug release from microparticles could 
be modified and was found to depend on the shapes of the microparticles. In vitro 
evaluation results indicate that the frequent dosage and side effects of pure PB may 
be reduced with the formulation of microparticles39. 
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Behzad Sharif Makhmal Zadeh et al36., performed on preparation and evaluation 
of sodium diclofenac loaded chitosan controlled release microparticles using factorial 
design.They conculed The sodium diclofenac loaded chitosan microparticles were 
prepared by ionic cross-linking with sodium tripolyphosphate successfully. Loading 
efficiency of sustained release microparticles to be touched by percentage of cross-
linking agent, Tween 80 and drug-chitosan proportion. Chitosan microparticles 
provided suitable sustained release pattern in the manner that with increasing in 
percentage of Tween 80, the released amount reduced.                                   
J. Ravi Kumar Reddy et al37., performed on formulation and evaluation of 
microparticles of metronidazole. They concluded the results of their study that 
delayed release microparticles of Metronidazole could be prepared by emulsion 
solvent evaporation technique by using the polymers like CAP, HPMCP, EL- 100 
and ES-100. The microparticles prepared using CAP, HPMCP, EL-100 and ES-100 
showed little amount of brittleness. This defect can be rectified by adding the 
plasticizer like castor oil, tween and span. The correct percentage of plasticizer to be 
added can be determined. Comparative drug release study revealed that the 
formulated product (microparticles) have more sustained effect than the marketed 
product. 
G.C.Bazzo et al38.,performed on Poly(3-hydroxybutyrate)/chitosan/ketoprofen or 
piroxicam composite microparticles: Preparation and controlled drug release 
evaluation.They conculed Pyridostigmine bromide (PB) is an anticholinesterase 
agent whose aqueous solubility is high and which has a short elimination half-life. Its 
dosage rate in the treatment of myastenia gravis is frequent due to the short half-life 
and it exhibits side effects. Microparticles designed to deliver a pharmaceutical 
active ingredient efficiently at the minimum dose and also to enhance stability, 
reduce side effects and modify drug release were prepared in this study using an 
acrylic polymer (Eudragit) as the vehicle by the spray-drying technique. The drug 
was either dissolved or dispersed in the polymeric solution and following the 
preparation of microparticles using different ratios of ingredients, characterization 
studies including the determination of shape, particle size distribution, amount 
loaded, release and stability of PB were performed. The results obtained were 
compared to those of pure PB. Drug release from microparticles could be modified 
and was found to depend on the shapes of the microparticles. In vitro evaluation 
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results indicate that the frequent dosage and side effects of pure PB may be reduced 
with the formulation of microparticles. 
NahedHegazy et al39., peformed on Preparation and in vitro evaluation of 
pyridostigmine bromide microparticles.They conculded Pyridostigmine bromide 
(PB) is an anticholinesterase agent whose aqueous solubility is high and which has a 
short elimination half-life. Its dosage rate in the treatment of myastenia gravis is 
frequent due to the short half-life and it exhibits side effects. Microparticles designed 
to deliver a pharmaceutical active ingredient efficiently at the minimum dose and 
also to enhance stability, reduce side effects and modify drug release were prepared 
in this study using an acrylic polymer (Eudragit) as the vehicle by the spray-drying 
technique. The drug was either dissolved or dispersed in the polymeric solution and 
following the preparation of microparticles using different ratios of ingredients, 
characterization studies including the determination of shape, particle size 
distribution, amount loaded, release and stability of PB were performed. The results 
obtained were compared to those of pure PB. Drug release from microparticles could 
be modified and was found to depend on the shapes of the microparticles. In vitro 
evaluation results indicate that the frequent dosage and side effects of pure PB may 
be reduced with the formulation of microparticles. 
KC Ofokansi et al40., performed on Formulation and Evaluation of Glutaraldehyde-
Crosslinked Chitosan Microparticles for the    Delivery of Ibuprofen.They conculded 
Entrapment of ibuprofen in glutaraldehyde-cross-linked chitosan microparticles can 
beexploited to target and control the release of the drug and possibly reduce its 
gastro-erosive sideeffects.Entrapment of ibuprofen in glutaraldehyde-cross-linked 
chitosan microparticles can beexploited to target and control the release of the drug 
and possibly reduce its gastro-erosive side effects. 
Rania O. Salama et al41 ., performed on Preparation and Evaluation of Controlled 
Release Microparticles for Respiratory Protein Therapy. They conculded All 
formulations had relatively good aerosolisation performance when compared to 
conventional dry powder inhalation (DPI) formulations although increasing PVA 
percentage had a negative effect on the aerosol performance in vitro. Analysis of the 
difference and similarity factors for the release profiles indicated significant 
differences with respect to PVA concentration. Furthermore, cell toxicity analysis 
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indicated PVA to have limited effect on cell viability after 24 h exposure. A series of 
protein-based inhalation formulations have been developed and tested, and shown to 
be suitable for controlled release in the respiratory tract. 
Priscileila Colerato Ferrar et al42., performed on Floating ability and drug release 
evaluation of gastroretentive microparticles system containing metronidazole 
obtained by spray drying.They conculded Floating microparticles were successfully 
obtained and characterized to potential gastroretentive effect, and possible use for 
gastric disease treatment, such as H. pylori infections. Floating microparticles 
composed by chitosan and one hydrophilic (HPMC) or one hydrophobic (EC) 
polymer were developed. Physicochemical characterization has shown the drug 
encapsulation and did not indicate chemical linkage occurrence between 
components. The microparticles floating ability study revealed no difference among 
the HPMC:CS samples, while microparticles containing a higher amount of EC 
presented poor flotation. The drug release study demonstrated better control of the 
MT release by EC:CS 1:3 sample, and similar profiles among HPMC:CS samples. 
However, the microparticles composed by HPMC and CS presented the best 
relationship between floating ability and controlled drug release and it is believed to 
be ideal for floating gastroretentive systems regarding safe administration. 
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LIST OF MATERIALS USED AND MANUFACTURERS 
List of Materials used and Manufactures 
S. No. MATERIALS MANUFACTURES 
1. Diclofenac sodium Aarti Drugs Limited, Chennai. 
2. Sulfamethoxazole Aarti Drugs Limited, Chennai. 
3. Pottasium dihydogen ortho phosphate Nice Chemicals Pvt., Ltd., Cochin, India. 
4. Sodium hydroxide S.D. Fine-Chem Ltd., Mumbai, India. 
5. Coconut oil Local Market 
6. Span – 80 Reachem Laboratory Chemical Private Limited, Chennai. 
7. Chitosan Yarrow Chem Products, Mumbai. 
8. Propylene glycol Reachem laboratory Chemicals Private Limited, Chennai. 
9. Poly ethylene glycol – 6000 Loba Chemie Private Limited, Mumbai, India. 
10. N – Cyclohexane Avantor Performance Materials India limited, Maharashtra, India. 
11. Carbomer-940  Merck specialities Pvt., Ltd., Mumbai, India 
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Drug Profile- Diclofenac sodium 
Drug                  :   Diclofenac sodium 
Structural formula    :     
 
Molecular formula : C14H10Cl2NNaO2. 
Molecular weight : 318.129 g/mol. 
Chemical name : Sodium{2-[(2,6-dichlorophenyl) amino] phenyl} acetate. 
Category : Non steroidal anti inflammatory drug (NASID) with analgesic actions. 
Dose: 25 mg, 50 mg, 75 mg, 100 mg and 150 mg. 
Description: White or slightly yellowish crystalline powder. 
Solubility: Soluble in water, pH 7.2, ethanol, methanol and acetone. 
Melting point : 283° C - 285°C43. 
MECHANISM OF ACTION 
The exact mechanism of action for diclofenac, like that of other NSAIDs, is 
unknown. They appear to have anti-inflammatory, anti-pyretic, and analgesic 
properties. These are thought to be mediated via inhibition of prostaglandins. This 
inhibition of prostaglandins is itself mediated via the inhibition of the cyclooxygenase 
(COX) enzyme. There are two forms of the COX enzyme. COX-1 is involved in 
‘housekeeping’ activities, such as mediating normal platelet function, regulating renal 
blood flow and providing cytoprotection of the gastric mucosa. COX-2 is involved in 
the response to tissue damage and mediates inflammation and pain. The COX-2 
inhibitors are more selective in their inhibition of COX-2 relative to COX-1. The 
COX-2 inhibitors have been associated with higher rates of cardiovascular adverse 
events and it is hypothesised that this effect is a result of relative COX-2/COX-1 
inhibition. While diclofenac is a traditional NSAID, it does display a preferential 
inhibition of COX-2 compared to COX-144. 
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Parmacokintics 
Bioavailabilty: Well absorbed undergoes first-pass metabolism; only 50-60% of a 
dose reaches systemic circulation as unchanged drug. Peak plasma concentration 
usually attained within about 1 hour. 
Onset: Single 50 mg or 100 mg doses of diclofenac potassium provide pain relief 
within 30 minutes. 
Duration: Pain relief lasts up to 8 hours following administration of single 50 mg or 
100 mg doses of diclofenac sodium.           
Food: Food delays time to reach peak plasma concentration but do not affect extent of 
absorption following administration as conventional Delayed-release or extended-
release tablets. 
Distribution 
Extent: Following oral adminitration, concentration in synovial fluid may exceed 
those in plasma. Plasma protein binding: >99%. 
Metabolism: Metabolised in the liver via hydroxylation and conjucation. Some 
metabolites may exhibit anti-inflammatory activity. 
Elimination: Excreted in urine (65%) and in feces via biliary elimination (35%) as 
metabolites.                          
Half-life: Oral preparations: 1-2 hours. Diclofenac epolamin Transdermal system. 
approximately 12 hours45.  
Drug interactions 
Drugs that can potentially interfere with diclofenac sodium include diuretics, 
other nonsteroidal anti-inflammatory drugs, and some herbal supplements. These 
interactions may increase the risk of kidney damage, reduce the activity of diuretics, 
or make ACE inhibitors less effective, among other things. If diclofenac sodium drug 
interactions are a concern, your healthcare provider may adjust your dosage or 
monitor you more closely46. 
Adverse effects 
Central nervous system: Headache 
Gastro intestional Tract: Stomach problems, including gas, 
bloatincramping, constipation, and diarrhea. Upset stomach and/or bleeding in your 
stomach, esophagus, or intestines. 
Skin : Rash. 
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Indications 
Mild-to-moderate pain. Moderate-to-severe pain alone or in combination with opioid 
analgesics. For relief of the signs and symptoms of osteoarthritis. For relief of the 
signs and symptoms of rheumatoid arthritis47. 
Dosage and adminitration  
Adult : For the relief of signs and symptoms of osteoarthritis 35 mg orally 3 times a 
day. For the relief of signs and symptoms of primary dysmenorrheal 50 mg orally 3 
times a daily. For the management of mild to moderate acute pain (oral, IV) and 
moderate to severe pain alone or in combination with opioid analgesics (IV) 150 mg 
per day48. 
Usual Adult Dose for Migraine: Diclofenac potassium for oral solution packets: 50 
mg (1 packet) orally once Comments: This drug is not indicated for the prophylactic 
therapy of migraine or for use in cluster headaches; the safety and efficacy of a 
second dose has not been established. 
Use: For acute treatment of migraine with or without aura. 
Usual Adult Dose for Dysmenorrhea: Diclofenac potassium immediate-release 
tablets: 50 mg orally 3 times a day Comments: An initial dose of 100 mg orally 
followed by 50 mg oral doses may provide better relief for some patients; initiate 
treatment upon appearance of the first symptoms and continue for a few days. 
Use: For the relief of signs and symptoms of primary dysmenorrhea. 
Usual Adult Dose for Osteoarthritis: Diclofenac free acid capsules: 35 mg orally 3 
times a day Diclofenac potassium immediate-release tablets: 50 mg orally 2 or 3 times 
a day Diclofenac sodium enteric-coated tablets: 50 mg orally 2 or 3 times a day or 75 
mg orally 2 times a day Maximum dose: 150 mg daily Diclofenac sodium extended-
release tablets: 100 mg orally once a day. 
Use: For the relief of signs and symptoms of osteoarthritis49. 
Contraindications 
Diclofenac sodium is contraindicated in the following patients: Known 
hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) 
to diclofenac or any components of the drug product50. 
Marketed products 
Diclogesic (Tab), Voltaren (Tab), Arthrotec (Tab), Arthrotec (injection), Reactin 
(Tab), Dylojet (Injection), Voveran-D (Tab), Amidol (Tab)51. 
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Drug Profile- Sulfamethoxazole 
Drug                    :    Sulfamethoxazole 
Structural formula        : 
 
Molecular formula : C10H11N3O3S 
Molecular weight : 253.276 g/mol 
Chemical name : 4-Amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide 
Category : Sulfamethoxazole is a bacteriostatic antibacterial agent 
Dose : 800 mg 
Description : White and white crystalline powder 
Solubility : Soluble in Ethanol, acetone, and methanol                                                                         
Melting point : 169°C52    
Mechanism of action 
Sulfamethoxazole is a sulfonamide drug that inhibits bacterial synthesis 
of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding 
to dihydropteroate synthetase. Sulfamethoxazole is bacteriostatic in nature. Inhibition 
of dihydrofolic acid synthesis decreases the synthesis of bacterial nucleotides and 
DNA.  
Sulfamethoxazole is normally adihydrofolate reductase inhibitor, which inhibits 
the reduction of dihydrofolic acid totetrahydrofolic acid. Studies have shown that 
bacterial resistance develops more slowly with the combination of the two drugs than 
with either Trimethoprim or Sulfamethoxazolealone. 
Sulfamethoxazole is a sulfonamide bacteriostatic antibiotic that is Bactium. 
Sulfamethoxazole competitively inhibits Bactrim. Sulfamethoxazole Competitively 
inhibits dihydropteroate synthase preventing the formation of dihydropteroic acid, a 
precursor of folic acid which is required for bacterial growth53. 
Parmacokinetics 
Absorption: Sulfamethoxazole is well-absorbed when administered topically. It is 
rapidly absorbed when it is orally administer.         
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Distribution: Sulfamethoxazole distributes into most body tissues as well as sputum, 
vaginal fluid, and middle ear fluid. It also crosses the placenta. About 70% of the drug 
is bound to plasma proteins. Its Tmax (or time to reach maximum drug concentration in 
plasma) occurs 1 to 4 hours after oral administration. The mean serum half-life of 
sulfamethoxazole is 10 hours. However, the half-life of the drug noticeably increases 
in people with creatinine clearance rates equal to or less than 30 ml/min. half-life of 
22–50 hours has been reported for people with creatinine clearances of less than 10 
ml/min. 
Metabolism: Sulfamethoxazole is metabolized in the human liver to at least 5 
metabolites. These metabolites are the N4-acetyl-, N4-hydroxy-, 5-methylhydroxy 
N4-acetyl-5-methylhydroxy-sulfamethoxazole metabolites, and an N-glucuronide 
conjugate. The CYP2C9 enzyme is responsible for the formation of the N4-hydroxy 
metabolite. In vitro studies suggest sulfamethoxazole is not a substrate of the P-
glycoprotein transporter. 
Excretion: Sulfamethoxazole is primarily renally excreted via glomerular filtration 
and tubular secretion.[ About 20% of the sulfamethoxazole in urine is the unchanged 
drug, about 15–20% is the N-glucuronide conjugate, and about 50–70 % is the 
acetylated metabolite. Sulfamethoxazole is also excreted in human milk54. 
Drug interaction 
Caution with concomitant CYP2C8, 2C9, or OCT2 substrates. May potentiate oral 
anticoagulants (eg, warfarin), hypoglycemics, phenytoin, methotrexate, digoxin; 
monitor. May be potentiated by indomethacin. May increase risk of thrombocytopenia 
with diuretics (esp. thiazides). Nephrotoxicity with cyclosporine in renal transplant. 
Megaloblastic anemia with >25mg/week doses of pyrimethamine. May antagonize 
tricyclic antidepressants. May interfere with assays for serum methotrexate, 
creatinine55. 
Adverse effects 
Central nervous system: Headache, dizziness. 
Gastro intestional tract: Nausea, diarrhea, Abdominal or stomach pain 
Musculo skeletal system: Lower pain back. 
Skin: Itching, joint or muscle pain, blistering, peeling, or loosening of the skin, 
changes in skin color pale skin, rash, red skin lesions, often with a purple center. 
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Indications 
Susceptible infections including UTIs (not for initial uncomplicated episodes), 
shigellosis, prophylaxis and treatment of Pneumocystis jiroveci pneumonia (PJP), 
travelers' diarrhea or acute exacerbations of chronic bronchitis in adults, acute otitis 
media in children56. 
Dosage and administration 
Adult: 1 DS tab or 2 regular tabs every 12 hours for 5 days (shigellosis, travelers' 
diarrhea), or 10–14 days (UTIs), or 14 days (bronchitis). PJP treatment: 15–20mg/kg 
per day trimethoprim (75–100mg/kg per day sulfamethoxazole) in equally divided 
doses every 6 hours for 14–21 days; PJP prophylaxis: one DS tab daily. Renal 
impairment (CrCl 15–30mL/min): reduce dose by ½; CrCl <15mL/min: not 
recommended. 
Child:  <2 months: see Contraindications. ≥2 months: 8 mg/kg per day trimethoprim 
(40 mg/kg per day of sulfamethoxazole) in 2 divided doses at 12 hour intervals for 5 
days (shigellosis) or 10 days (otitis media, UTIs). PJP treatment: as adult; PJP 
prophylaxis or renal impairment57. 
Contraindications 
History of drug-induced immune thrombocytopenia with use of trimethoprim and/or 
sulfonamides. Megaloblastic anemia due to folate deficiency. Pediatrics <2 months. 
Marked hepatic damage. Severe renal insufficiency when renal status cannot be 
monitored58. 
Marketed products 
Gantanol (Tab), Azo Gantanol (Tab), Bactrim (Tab), Bactrim DS (Tab) and Septra 
DS (Tab)59. 
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POLY ETHYLENE GLYCOL 
Non proprietary names   
BP: Macrogols 
JP:  Macrogol 400 
      Macrogol 1500 
      Macrogol 4000 
      Macrogol 6000 
      Macrogol 20000 
   PhEur  : Macrogols 
  USP-NF: Polyethylene Glycol  
Synonyms:    
Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; macrogola; PEG; Pluriol E; 
polyoxyethylene glycol. 
Structural formula:                   
 
Chemical name:     A-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl) 
Empirical formula:    H(OCH2CH2)nOH      
Molecular weight:   300 g/mol to 10,000,000 g/mol  
Melting point:   55–63°C for PEG 6000 
Fuctional category:   Ointment base; plasticizer; solvent; suppository Base; tablet 
and capsule lubricant60. 
DESCRIPTION:  
The USP32–NF27 describes polyethylene glycol as being an addition polymer 
of ethylene oxide and water. Polyethylene glycol grades 200–600 are liquids; grades 
1000 and above are solids at ambient temperatures. Liquid grades (PEG 200–600) 
occur as clear, colorless or slightly yellow-colored, viscous liquids. They have a slight 
but characteristic odor and a bitter, slightly burning taste.PEG 600 can occur as a solid 
grades (PEG>1000) are white or off-white in color, and range in consistency from 
pastes to waxy flakes. They have a faint, sweet odor. Grades of PEG 6000 and above 
are available as free flowing milled powders. 
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Solubility: Polyethylene glycols are soluble in water Liquid polyethylene glycols are 
soluble in acetone, alcohols, benzene, glycerin, glycols. Solid polyethylene glycols 
are soluble in acetone, soluble in aliphatic hydrocarbons and ether but insoluble in 
fats, fixed oils, and mineral oil, alcohols, benzene, glycerin, and glycols. Solid 
polyethylene glycols are soluble in acetone dichloromethane, ethanol (95%), and 
methanol; they are slightly soluble in fats fixed oils, and mineral oil.                                                     
Stability and storage conditions:  Polyethylene glycols are chemically stable in air 
and in solution, although grades with a molecular weight less than 2000 are 
hygroscopic. Polyethylene do not support microbial growth and do not become 
rancid. Polyethylene glycols and aqueous polyethylene glycol solutions can be 
sterilized by autoclaving, filtration, or gamma irradiation61. 
Incompatibilities: Chemical reactivity of polyethylene the glycols is mainly confined 
to the two terminal hydroxyl groups, which can be either esterified or etherified. 
However, all grades can exhibit all grades can exhibit some oxidizing activity owing 
to the presence of peroxide impurities and secondary products formed by 
autoxidation. Liquid and solid polyethylene glycol grades may be incompatible with 
some coloring agents. The antibacterial activity of certain antibiotics is reduce in 
polyethylene glycol bases particular that of penicillin and bacitracin. The preservative 
efficacy of the parabens62. 
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CHITOSAN 
Non proprietary names:          
BP: Chitosan Hydrochloride 
PhEur: Chitosan Hydrochloride      
Synonyms:  2-Amino-2-deoxy-(1,4)-b-D-glucopyranan; chitosan hydrochloridum; 
deacetylated chitin; deacetylchitin; b-1,4-poly-D-glucosamine; 
Structural formula:       
                                                                                    
 
Chemical name: Poly-b-(1,4)-2-Amino-2-deoxy-D-Glucose. 
Empirical formula:  (C6H11NO4)n  
Molecular weight:   10,000–10,00,00063. 
Applications:    
Chitosan is used in cosmetics and is under investigation for use in a number of 
pharmaceutical formulations. The suitability and performance of chitosan as a 
component of pharmaceutical formulations for drug delivery applications has been 
investigated in numerous studies. These include controlled drug delivery applications 
use as a component of mucoadhesive forms, rapid release dosage forms, improved 
peptide delivery colonic drug delivery systems and use for gene delivery.  
Chitosan has been processed into several pharmaceutical forms including gels 
films, beads, microspheres, tablets, and coatings for liposomes. Furthermore, chitosan 
may be processed into drug delivery systems using several techniques including 
spray-drying cocervation, direct compression, and conventional granulation processes. 
Fuctional category: Coating agent; disintegrant; film- forming agent; mucoadhesive; 
tablet binder; viscosity increasing agent64. 
Description: Chitosan occurs as odorless, white or creamy-white powder or flakes. 
Fiber formation is quite precipitation and common during  the chitosan may look 
‘cotton like’. 
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Solubility: Sparingly soluble in water; practically insoluble in ethanol (95%), other 
organic solvents, and neutral or alkali solutions at pH above approximately 6.5. 
Chitosan dissolves solvents, readily in dilute and  concentrated solutions of most 
organic removed.                                            
Stability and storage conditions: Chitosan powder is a stable material at room 
temperature, although  it is hygroscopic after drying. Chitosan should be stored in a 
tightly closed container in a cool, dry place. The PhEur 6.5 specfies that chitosan 
should be stored at a  temperature of 2–8°C. 
Incompatibilities: Chitosan is incompatible with strong oxidizing agents65.   
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PROPYLENE GLYCOL 
 Non proprietary names: 
JP           :  Propylene glycol 
PhEur    :  Propylene glycolum 
USP     :   Propylene Glycol 
SYNONYMS: 1,2-Dihydroxypropane; E1520; 2-Hydroxypropanol; methyl ethylene 
glycol; methyl glycol; propane-1,2-diol; propylene glycolum. 
Structural formula:   
 
Chemical name: 
             Propane-1,2- diol 1,2 –dihydroxypropane 1,2-popanediol methyl glycol                                   
Empirical formula: C3H8NO2 
Molecular weight: 76. 10 g/cm3 
 Melting point: - 59 ° C 
Solubility: Soluble in water, Soluble in ethanol, soluble in diethyl ether, Soluble in 
acetone, Soluble in chloroform. 
(Lowther A et al. Systemic contact dermatitis from propylene glycol.Dermatitis 2008; 
19(2): 105–108.) 
Stability and Storage Conditions : At cool temperatures, propylene glycol is stable 
in a well-closed container, but at high temperatures,in the open, it tends to oxidize, 
giving rise to products such as propionaldehyde, lactic acid, pyruvic acid, and acetic 
acid. Propylene glycol is chemically stable when mixed with ethanol (95%), glycerin, 
or water; aqueous solutions may be sterilized by autoclaving. 
Applications : Propylene glycol is used as a solvent in many pharmaceuticals, 
including oral,  injectable and topical formulations, such  as  for diazepam and 
lorazepam which are  insoluble in water. Like ethylene glycol, propylene glycol is 
able to lower the freezing point of water, and so it is used as aircraft de-icing fluid. 
Fuctional category: Food additives, Pharmaceutical aid treatment and prophylaxis of 
acetonemia in animals. 
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Description: Propylene glycol is a clear, colorless, viscous, practically odorless 
liquid, with a sweet, slightly acrid taste resembling that of glycerin. 
Incompatibilities: The demixing behavior of 20 repsentatives of  the system oligo 
propylene glycol is investigated at pressures up to 1500 bar. The degree of 
oligomerization range from 2 to 5 for the first component. The experimental results 
are compared with those for the previously studied system oligo propylene 
glycol/oligoisobutane. In both cases the observed upper critical temperatures increase 
with the number of monomeric units of the less polar component66. 
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COCONUT OIL 
Non proprietary names:  
JP           :    Coconut Oil 
PhEur     :    Coconut Oil, Refined 
USP-NF : Coconut Oil    
Chemical name:  
EINECS 263-194-8; ((Coconut oil  alkyl) amino) butyric acid, sodium salt; 2-
Aminobutyric acid sodium salt; SCHEMBL15820003; Butanoic acid, 2-amino-, N-
coco alkyl derivs, monosodium salts; Butanoic acid, 2-amino-, N-cocoalkyl derivs., 
monosodium salts. 
Synonyms:  Aceite de coco; cocois oleum raffinatum; coconut butter; copra oil; 
oleum coc Pureco 76; refined coconut oil. 
Empirical formula: C4H8NNaO2. 
Structural formula:  
 
Molecular weight: 640–680 g/mol 
(CF Hung et al. The effect of oil components on the physico chemical properties and 
drug delivery of emulsions: tocol emulsion versus lipid emulsion. International 
Journal  Pharmacy and research, 2007; 335(1–2): 193–202.) 
Melting point: 76° C 
Applications: Coconut oil has traditionally been used in ointments where it forms a 
readily                                                                                       absorbable base. It has 
been used particularly in preparations intended for application to the scalp, where it 
could be applied as a solid but would liquefy when applied to the skin. Coconut oil is 
readily saponified by strong alkalis even in the cold and, as the soap produced is not 
readily precipitated by sodium chloride, it has been used in the making of ‘marine’ 
soap. Coconut oil may be used in the formulation of a range of other preparations 
including emulsions and nanoemulsions, intranasal solutions and rectal capsules and 
suppositories. In addition, coconut oil has been reported to have antifungal activity 
against a range of Candida species67.  
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Fuctional  category :  
Coconut oil is sometimes applied to the skin as a moisturizer, for neonatal health, and 
to treat eczema and a skin condition called psoriasis. Coconut oil is also used 
in hair products to prevent hair damage.       
Solubility: Solubility in water: Coconut oil forms a white homogenous mixture 
Stability and Storage Conditions: Coconut oil remains edible, and mild in taste and 
odor, for several years under ordinary storage conditions. However, on exposure to 
air, the oil readily oxidizes and becomes rancid, acquiring an unpleasant odor and 
strong acid taste. Store in a tight, well-filled container, protected from light at a 
temperature not exceeding 258C. Coconut oil may be combustible at high 
temperature, and may spontaneously heat and ignite if stored under hot and wet 
conditions. 
Description: Coconut oil generally occurs as a white to light-yellow mass or colorless 
or light-yellow clear oil, with a slight odor characteristic of coconut and a mild taste. 
Refined coconut oil is a white or almost white unctuous mass. 
Incompatibilities: Coconut oil reacts with oxidizing agents, acids and alkalis. 
Polyethylene is readily permeable to coconut oil68.                                                                                 
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SPAN-80 
Non proprietary names: None adopted. 
Synonyms: Afrodit; aluminum-saponite; auxite; cathkinite; ferroan saponite; 
griffithite; licianite; lucianite; piotine; zebedassite. 
Structural formula: Saponite is composed of two tetrahedral layers formed by 
phylosilicate sheets and one octahedral layer. Common impurities include manganese, 
nickel, phosphorus, potassium, and titanium. 
Chemical name:Saponite 
Empirical formula: (Ca05Na)3(Mg,Fe2þ)3(Si,Al)4O10(OH)2_4H2O 
Solubility: Saponite is composed of two tetrahedral layers formed by phylosilicate 
sheets and one octahedral layer. Common impurities include manganese, nickel, 
phosphorus, potassium, and titanium. 
Stability and Storage Conditions: 
Saponite is a stable material and should be stored in a cool, dry place. 
Applications: Occurring clays such as magnesium Aluminum silicates and is 
therefore suitable for use in pharmaceutical formulation applications as an adsorbent 
viscosity-increasing agent, suspending agent, or as an oil-in- water emulsifying agent. 
Saponite, as a component magnesium aluminium silicates, is useful as a formulation 
component in semisolid cosmetic and health care products. 
Fuctional  category: Adsorbent; emulsifying agent; viscosity increasing agent. 
Description: Saponite occurs as a white to off-white, dull powder composed of fine-
grained. The material is greasy or soapy to the touch and swells on the addition of 
water. 
Incompatibilities: May generate heat in contact with hydrofluoric acid69. 
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CARBOMER – 940 
Non proprietary names:         
BP             :       Carbomers 
PhEur        :       Carbomers 
USP-NF    :       Carbomer 
Synonyms: Acrypol; Acritamer; acrylic acid polymer; carbomera; Carbopol;carboxy 
polymethylene; polyacrylic acid; carboxyvinyl polymer; Pemulen; Tego Carbomer. 
Structural formula:               
 
 
Chemical name: Carbomer 
Empirical formula: ( C3H4O2)n 
Molecular weight:       104 400 g/mol 
Melting point: 260°C. 
Solubility: Swellable in water and glycerin and, after neutralization, in ethanol (95%). 
Carbomers do not dissolve but merely swell to a remarkable extent, since they are 
three-dimensionally crosslinked microgels70. 
Stability and Storage Conditions: 
Carbomers are stable, hygroscopic materials that may be heated at temperatures below 
1048C for up to 2 hours without affecting their thickening efficiency. However, 
exposure to excessive temperatures can result in discoloration and reduced stability. 
Complete decomposition occurs with heating for 30 minutes at 2608C. 
Applications: Carbomers are used in liquid or semisolid pharmaceutical formulations 
as rheology modifiers. Formulations include creams, gels, lotions and ointments for 
use in ophthalmic, rectal, topical and vaginal preparations. 
Functional  category: Bioadhesive material; controlled-release agent; emulsifying 
agent; emulsion stabilizer; rheology modifier; stabilizing agent; tablet binder.            
 Description: Carbomers are white-colored, ‘fluffy’, acidic, hygroscopic powders 
with a characteristic slight odor. A granular carbomer is also available (Carbopol 
71G). 
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Incompatibilities: Carbomers are discolored by resorcinol and are incompatible with 
phenol, cationic polymers, strong acids, and high levels of electrolytes. Certain 
antimicrobial adjuvants should also be avoided or used at low levels. Trace levels of 
iron and other transition metals can catalytically degrade carbomer dispersions. 
Certain amino-functional actives form complexes with carbomer; often this can be 
prevented by adjusting the pH of the dispersion and/or the solubility parameter by 
using appropriate alcohols and polyols. Carbomers also form pH-dependent 
complexes with certain polymeric excipients. Adjustment of pH and/or solubility 
parameter can also work in this situation71.  
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AIM AND PLAN OF WORK 
The aim of this present work was to development of topical gels containing 
chitosan-and PEG-based microparticles loaded with dual drugs (diclofenac sodium 
and sulfamethoxazole) for bacterial skin infections.  
The plan of this work can be outlined below, 
• To carry out the preformulation studies for API 
• Description 
• Solubility 
• Melting point 
• Drug excipients compatibility studies 
• Physical observation 
• Formulation of microparticle contains diclofenac sodium and 
sulfamethoxazole.  
• Evaluation of microparticle formulations 
 Percentage yield 
 Drug content 
 IR studies 
 Particle size determination by sieving method procedure 
 Dissolution studies 
• Evaluation of microparticle formulations in gel 
 Gel preparation 
 Gel evaluation – Spreadability and consistency test 
 Microparticles mixed with gel 
 Permeation studies procedure 
 Release kinetics 
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LIST OF MATERIALS USED AND MANUFACTURERS 
List of Materials used and Manufactures 
S. No.    MATERIALS MANUFACTURES 
1 Diclofenac sodium Aarti Drugs Limited, Chennai. 
2 Sulfamethoxazole Aarti Drugs Limited, Chennai. 
3 Pottasium dihydogen ortho phosphate Nice Chemicals Pvt., Ltd., Cochin, India. 
4 Sodium hydroxide S.D. Fine-Chem Ltd., Mumbai, India. 
5 Coconut oil Local Market 
6 Span – 80 Reachem Laboratory Chemical Private Limited, Chennai. 
7 Chitosan Yarrow Chem Products, Mumbai. 
8 Propylene glycol Reachem laboratory Chemicals Private Limited, Chennai. 
9 Poly ethylene glycol - 6000 Loba Chemie Private Limited, Mumbai, India. 
10 N – Cyclohexane Avantor Performance Materials India limited, Maharashtra, India. 
11 Carbomer-940  Merck specialities Pvt., Ltd., Mumbai, India 
 
                           INSTRUMENTS USED AND MANUFACTURERS 
                     List of Instruments used and Manufactures 
S. No.    INSTRUMENTS          MANUFACTURES 
1 Melting point Apparatus Guna Enterprises, Chennai. 
2 Mechanical Stirrer Remi motors Limited. Mumbai, India. 
3 pH – Meter  Toshniwal instruments Mfg. Pvt. Ltd, Ajmer, India 
4 Water Bath Guna Enterprises, Chennai. 
5 U V –Spectrophotometer SHIMADZU 8400S, Japan. 
6 Dissolution Apparatus Labindia analytical Instruments Limited, India. 
7 Sieve sets Jayant scientific IND, Mumbai. 
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Methodology 
Preformulation studies 
Preformulation may be described as the process of optimizing a drug through 
determination of those physical and chemical properties considered important in the 
formulation of a stable, effective and safe dosage form. The possible interactions with 
the various components intended for use in the final drug product are also considered. 
It is an effort that encompasses the study of such parameters as dissolution, 
polymorphic forms and crystal size and shape, pH profile of stability and drug – 
excipients interactions, which may have a profound effect on a drug’s physiological 
availability and physical and chemical stability. Preformulation involves the 
application of biopharmaceutical principles to the physicochemical parameters of 
drug substance are characterized with the goal of designing optimum drug delivery 
system.  
Scope 
Use of preformulation parameters maximizes the chances in formulating an 
acceptable, safe, efficacy and stable product. At the same time provides the basis for 
optimization of drug product quality. 
Some of the important parameters evaluated during preformulation studies are 
following 
• Physicochemical evaluation of drug molecule 
• Description 
• Solubility 
• Melting point 
• Compatibility studies of the drug with excipients 
Description 
It is the initial evaluation during preformulation studies which assess the 
colour, odour, nature and taste of the substance. This was only a descriptive test76-78.  
Solubility 
Aqueous solubility is an important physicochemical property of drug 
substance, which determines its systemic absorption and in turns its therapeutic 
efficacy.  
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Table-1 
Solubility Specifications 
Descriptive terms Approximate volume of solvent in 
millilitres per gram  of solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10,000 
Practically insoluble More than 10,000 
 
Melting point 
The temperature at which the first particle of the substance completely melts is 
regarded as melting point of the substance. The temperature at which the first particle 
start to melt and last particle completely melts is regarded as melting range76. Melting 
point determination was done for pure diclofenac sodium and sulfamethoxazole 
(separately and combine) by using melting point apparatus. Small amount of pure 
diclofenac sodium and sulfamethoxazole and combination of diclofenac sodium, 
sulfamethoxazole were taken in glass capillary tube whose one end was sealed by 
flame. The capillary tube containing samples was kept in the melting point apparatus 
and the melting point was noted.  
Physical drug-excipients compatibility studies 
In the some dosage form the drug is in intimate contact with one or more 
excipients, the latter could affect the stability of the drug. Knowledge of drug-
excipients interactions therefore is very useful to the formulators in selecting 
appropriate excipients. 
Compatibility studies were performed by preparing blend of different 
excipients with drug and stored at room temperature for one week. The initial state of 
mixture was noted and further evaluation for the possible occurrence of any 
interactions was checked after one week.  
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Standard curve of diclofenac sodium and sulfamethoxazole 
Preparation of 0.2 M potassium dihydrogen phosphate 
27.218 gm of potassium dihydrogen phosphate was dissolved in small quantity 
of distilled water and make upto 1000 ml with distilled water. 
Preparation of 0.2 M sodium hydroxide solution 
8 gm of sodium hydroxide was dissolved in little amount of distilled water and 
make upto 1000 ml with distilled water. 
Preparation of phosphate solution pH 7.4 
500 ml of 0.2 M Potassium dihydrogen phosphate solution and 391 ml of 0.2 
M sodium hydroxide solution was mixed together and made upto 2000 ml with 
distilled water. Then it was adjusted to pH 7.4. 
Preparation of diclofenac sodium standard curve using phosphate buffer 
solution pH 7.4 
Accurately weighed 50 mg of diclofenac sodium and transferred to 50 ml 
standard measuring flask (SMF), small amount of pH 7.4 was added to dissolve 
diclofenac sodium, then the volume was make upto 50 ml with pH 7.4 to get a 
concentration of 1 mg/ml. From the above solution 20 ml was pipette out into a 200 
ml volumetric flask and made upto the mark using phosphate buffer solution pH 7.4, 
to get a concentration of 100 µg/ml. It’s a stock solution. From the stock solution, 
aliquots of 2 ml, 4 ml, 6 ml, 8 ml, 10 ml, 12 ml, 14 ml, 16 ml, 18 ml and 20 ml were 
pipetted out into a series of 100 ml volumetric flasks and made upto the 100 ml mark 
with phosphate buffer solution pH 7.4 to get drug concentration in the range of 2 to 20 
µg/ml. The absorbance of the resulting solution was then measured at 276 nm in a UV 
double beam spectrophotometer against phosphate buffer solution pH 7.4 as blank. 
The standard curve was obtained by plotting concentration (µg/ml) values in X-axis 
and absorbance values in Y-axis. 
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Table-2 
Diclofenac sodium standard curve using phosphate buffer solution pH 7.4 
S. No. Concentration(µg/ml) 
Absorbance at 276 nm Average 
with SD* 1st time 2nd time 3rd time 
1 2 0.086 0.091 0.083 0.087±0.004 
2 4 0.147 0.153 0.144 0.148±0.005 
3 6 0.219 0.205 0.212 0.212±0.007 
4 8 0.279 0.267 0.276 0.274±0.006 
5 10 0.363 0.361 0.365 0.363±0.002 
6 12 0.409 0.403 0.413 0.408±0.005 
7 14 0.499 0.487 0.481 0.489±0.009 
8 16 0.556 0.548 0.549 0.551±0.004 
9 18 0.623 0.629 0.624 0.625±0.003 
10 20 0.701 0.711 0.705 0.706±0.005 
 
 
Figure-1 
Diclofenac sodium standard curve using phosphate buffer solution pH 7.4 
 
MATERIAL AND METHOD 
55 
Preparation of Sulfamethoxazole standard curve using phosphate buffer solution 
pH 7.4: 
Accurately weighed 100 mg of sulfamethoxazole and transferred to 100 ml 
SMF, small amount of pH 7.4 was added to dissolve diclofenac sodium, and then the 
volume was make upto 100 ml with pH 7.4 to get a concentration of 1 mg/ml. From 
the above solution 20 ml was pipette out into a 200 ml volumetric flask and made 
upto the mark using phosphate buffer solution pH 7.4, to get a concentration of 100 
µg/ml. It’s a stock solution. From the stock solution, aliquots of 2 ml, 4 ml, 6 ml, 8 
ml, 10 ml, 12 ml, 14 ml, 16 ml, 18 ml and 20 ml were pipetted out into a series of 100 
ml volumetric flasks and made upto the 100 ml mark with phosphate buffer solution 
pH 7.4 to get drug concentration in the range of 2 to 20 µg/ml. The absorbance of the 
resulting solution was then measured at 257 nm in a UV double beam 
spectrophotometer against phosphate buffer solution pH 7.4 as blank. The standard 
curve was obtained by plotting concentration (µg/ml) values in X-axis and absorbance 
values in Y-axis. 
Table-3 
Sulfamethoxazole standard curve using phosphate buffer solution pH 7.4 
S. No. Concentration (µg/ml) 
Absorbance at 257 nm Average with SD*1st time 2nd time 3rd time
1 2 0.134 0.136 0.135 0.1350±0.0010 
2 4 0.279 0.271 0.275 0.2750±0.0040 
3 6 0.395 0.393 0.391 0.3930±0.0020 
4 8 0.524 0.525 0.521 0.5233±0.0021 
5 10 0.668 0.663 0.667 0.6660±0.0026 
6 12 0.791 0.799 0.782 0.7907±0.0085 
7 14 0.902 0.914 0.919 0.9117±0.0087 
8 16 1.044 1.041 1.043 1.0427±0.0015 
9 18 1.18 1.15 1.17 1.1667±0.0153 
10 20 1.31 1.27 1.36 1.3133±0.0451 
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Figure-2 
Sulfamethoxazole standard curve using phosphate buffer solution pH 7.4 
 
Preparation of combination of Diclofenac sodium and Sulfamethoxazole 
standard curve using phosphate buffer solution pH 7.4: 
Accurately weighed 50 mg of diclofenac sodium and 100 mg of 
sulfamethoxazole and transferred to 50 ml SMF, small amount of pH 7.4 was added to 
dissolve diclofenac sodium, and then the volume was make upto 50 ml with pH 7.4 to 
get a concentration of 1 mg/ml for diclofenac sodium and 2 mg/ml for 
sulfamethoxazole. From the above solution 20 ml was pipette out into a 200 ml 
volumetric flask and made upto the mark using phosphate buffer solution pH 7.4 to 
get a concentration of 100 µg/ml for diclofenac sodium and 200 µg/ml for. It’s a stock 
solution. From the stock solution, aliquots of 2 ml, 4 ml, 6 ml, 8 ml, 10 ml, 12 ml, 14 
ml, 16 ml, 18 ml and 20 ml were pipetted out into a series of 100 ml SMF and made 
upto the 100 ml mark with phosphate buffer solution pH 7.4 to get drug concentration 
in the range of 2 to 20 µg/ml for diclofenac sodium. The absorbance of the resulting 
solution was then measured at 257 nm in a UV double beam spectrophotometer 
against phosphate buffer solution pH 7.4 as blank. From the stock solution, aliquots of 
1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 9 ml, and 10 ml were pipetted out into a 
series of 100 ml SMF and made upto the 100 ml mark with phosphate buffer solution 
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pH 7.4 to get drug concentration in the range of 2 to 20 µg/ml for sulfamethoxazole. 
The absorbance of the resulting solution was then measured at 276 nm in a UV double 
beam spectrophotometer against phosphate buffer solution pH 7.4 as blank. The 
standard curve was obtained by plotting concentration (µg/ml) values in X-axis and 
absorbance values in Y-axis79. 
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Table-4 
Diclofenac sodium standard curve in combination with Sulfamethoxazole using 
phosphate buffer solution pH 7.4 
Concentration 
(µg/ml) 
Diclofenac sodium at 276 nm 
1st time 2nd time 3rd time Average with SD* 
2 0.134 0.122 0.114 0.1233 ± 0.0101 
4 0.277 0.249 0.25 0.2587 ± 0.0159 
6 0.411 0.368 0.374 0.3843 ± 0.0233 
8 0.526 0.511 0.496 0.5110 ± 0.0150 
10 0.654 0.618 0.625 0.6323 ± 0.0191 
12 0.762 0.734 0.754 0.7500 ± 0.0144 
14 0.867 0.865 0.877 0.8697 ± 0.0064 
16 0.998 1.02 1.016 1.0113 ± 0.0117 
18 1.136 1.135 1.136 1.1357 ± 0.0006 
20 1.271 1.235 1.283 1.2630 ± 0.0250 
 
 
Figure-3 
Diclofenac sodium standard curve in combination with Sulfamethoxazole using 
phosphate buffer solution pH 7.4 
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Table-5 
Sulfamethoxazole standard curve in combination with Diclofenac sodium using 
phosphate buffer solution pH 7.4 
Concentration 
(µg/ml) 
Sulfamethoxazole at 257 nm 
1st time 2nd time 3rd time Average with SD 
2 0.178 0.176 0.168 0.1740 ± 0.0053 
4 0.366 0.361 0.365 0.3640 ± 0.0026 
6 0.544 0.537 0.543 0.5413 ± 0.0038 
8 0.692 0.739 0.718 0.7163 ± 0.0235 
10 0.878 0.903 0.903 0.8947 ± 0.0144 
12 1.027 1.071 1.087 1.0617 ± 0.0311 
14 1.177 1.26 1.265 1.2340 ± 0.0494 
16 1.36 1.486 1.46 1.4353 ± 0.0665 
18 1.547 1.649 1.631 1.6090 ± 0.0544 
20 1.679 1.798 1.841 1.7727 ± 0.0839 
 
 
Figure-4 
Sulfamethoxazole standard curve in combination with Diclofenac sodium using 
phosphate buffer solution pH 7.4
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Preparation of microparticle 
Preparation of Diclofenac sodium microparticle without chitosan: 
Microparticles containing Diclofenac sodium without chitosan were prepared 
following cold/hot-dispersion method. Weighed accurately about 6 gm of Poly 
ethylene glycol-6000 (PEG-6000) in a china dish and allowed to melt in a water bath. 
When PEG-6000 was completely melted, about 50 mg of diclofenac sodium was 
added to the molten PEG-6000 and stirred well until diclofenac sodium was dissolved 
completely.  
In 250 ml beaker, 50 ml coconut oil was taken and 100 mg of Span-80 was 
added and mixed well by using mechanical stirrer for about 5 minutes. Then the 
melted mixture (PEG-6000+Diclofenac sodium) was added to the coconut oil and 
span-80 mixture in a thin film. The preparations were allowed to mix in mechanical 
stirrer for about 1 hour at 800 rpm.  
After 1 hr 50 ml of n-hexane was taken in a burette and it was added dropwise 
to the above preparation for about 45-60 min. with continuous stirring. Then resulting 
product was filtered, collected and dried at room temperature until it was used further. 
Preparation of Sulfamethoxazole microparticle without chitosan: 
Microparticles containing Sulfamethoxazole without chitosan were prepared 
following cold/hot-dispersion method. Weighed accurately about 6 gm of PEG-6000 
in a china dish and allowed to melt in a water bath. When PEG-6000 was completely 
melted, about 100 mg of sulfamethoxazole was added to the molten PEG-6000 and 
stirred well until sulfamethoxazole was dissolved completely.  
In 250 ml beaker, 50 ml coconut oil was taken and 100 mg of Span-80 was 
added and mixed well by using mechanical stirrer for about 5 minutes. Then the 
melted mixture (PEG-6000+sulfamethoxazole) was added to the coconut oil and span-
80 mixture in a thin film. The preparations were allowed to mix in mechanical stirrer 
for about 1 hour at 800 rpm.  
After 1 hr 50 ml of n-hexane was taken in a burette and it was added dropwise 
to the above preparation for about 45-60 min. with continuous stirring. Then resulting 
product was filtered, collected and dried at room temperature until it was used further. 
Preparation of Diclofenac sodium and Sulfamethoxazole microparticle without 
chitosan: 
Microparticles containing Diclofenac sodium and Sulfamethoxazole without 
chitosan were prepared following cold/hot-dispersion method. Weighed accurately 
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about 6 gm of PEG-6000 in a china dish and allowed to melt in a water bath. When 
PEG-6000 was completely melted, about 50 mg of diclofenac sodium and 100 mg of 
sulfamethoxazole was added to the molten PEG-6000 and stirred well until diclofenac 
sodium and sulfamethoxazole was dissolved completely.  
In 250 ml beaker, 50 ml coconut oil was taken and 100 mg of Span-80 was 
added and mixed well by using mechanical stirrer for about 5 minutes. Then the 
melted mixture (PEG-6000+ diclofenac sodium and sulfamethoxazole) was added to 
the coconut oil and span-80 mixture in a thin film. The preparations were allowed to 
mix in mechanical stirrer for about 1 hour at 800 rpm.  
After 1 hr 50 ml of n-hexane was taken in a burette and it was added dropwise 
to the above preparation for about 45-60 min. with continuous stirring. Then resulting 
product was filtered, collected and dried at room temperature until it was used further. 
Preparation of Diclofenac sodium microparticle with chitosan: 
Microparticles containing Diclofenac sodium with chitosan were prepared 
following cold/hot-dispersion method. Microparticles containing Diclofenac sodium 
with chitosan were prepared following cold/hot-dispersion method. Weighed 
accurately about 6 gm of PEG-6000 in a china dish and allowed to melt in a water 
bath. When PEG-6000 was completely melted, 0.75 ml of propylene glycol was 
added to the molten PEG-6000 and mixed well. To the above mixture about 75 mg of 
chitosan was added and allowed to dissolve and then 50 mg of diclofenac sodium was 
added and stirred well until diclofenac sodium was dissolved completely.  
In 250 ml beaker, 50 ml coconut oil was taken and 100 mg of Span-80 was 
added and mixed well by using mechanical stirrer for about 5 minutes. Then the 
melted mixture (PEG-6000+ propylene glycol+chitosan+diclofenac sodium) was 
added to the coconut oil and span-80 mixture in a thin film. The preparations were 
allowed to mix in mechanical stirrer for about 1 hour at 800 rpm.  
After 1 hr 50 ml of n-hexane was taken in a burette and it was added dropwise 
to the above preparation for about 45-60 min. with continuous stirring. Then resulting 
product was filtered, collected and dried at room temperature until it was used further. 
Preparation of sulfamethoxazole microparticle with chitosan: 
Microparticles containing Sulfamethoxazole with chitosan were prepared 
following cold/hot-dispersion method. Weighed accurately about 6 gm of PEG-6000 
in a china dish and allowed to melt in a water bath. When PEG-6000 was completely 
melted, 0.75 ml of propylene glycol was added to the molten PEG-6000 and mixed 
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well. To the above mixture about 75 mg of chitosan was added and allowed to 
dissolve and then 50 mg of diclofenac sodium and 100 mg of sulfamethoxazole was 
added and stirred well until diclofenac sodium and sulfamethoxazole was dissolved 
completely.  
In 250 ml beaker, 50 ml coconut oil was taken and 100 mg of Span-80 was 
added and mixed well by using mechanical stirrer for about 5 minutes. Then the 
melted mixture (PEG-6000+ propylene glycol+chitosan+sulfamethoxazole) was 
added to the coconut oil and span-80 mixture in a thin film. The preparations were 
allowed to mix in mechanical stirrer for about 1 hour at 800 rpm.  
After 1 hr 50 ml of n-hexane was taken in a burette and it was added dropwise 
to the above preparation for about 45-60 min. with continuous stirring. Then resulting 
product was filtered, collected and dried at room temperature until it was used further. 
Preparation of diclofenac sodium and sulfamethoxazole microparticle with 
chitosan: 
Microparticles containing Diclofenac sodium and Sulfamethoxazole with 
chitosan were prepared following cold/hot-dispersion method. Weighed accurately 
about 6 gm of PEG-6000 in a china dish and allowed to melt in a water bath. When 
PEG-6000 was completely melted, 0.75 ml of propylene glycol was added to the 
molten PEG-6000 and mixed well. To the above mixture about 75 mg of chitosan was 
added and allowed to dissolve and then 50 mg of diclofenac sodium and 100 mg of 
sulfamethoxazole was added and stirred well until diclofenac sodium and 
sulfamethoxazole were dissolved completely.  
In 250 ml beaker, 50 ml coconut oil was taken and 100 mg of Span-80 was 
added and mixed well by using mechanical stirrer for about 5 minutes. Then the 
melted mixture (PEG-6000+ propylene glycol+chitosan+diclofenac 
sodium+sulfamethoxazole) was added to the coconut oil and span-80 mixture in a thin 
film. The preparations were allowed to mix in mechanical stirrer for about 1 hour at 
800 rpm.  
After 1 hr 50 ml of n-hexane was taken in a burette and it was added dropwise 
to the above preparation for about 45-60 min. with continuous stirring. Then resulting 
product was filtered, collected and dried at room temperature until it was used 
further80. 
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Table-6 
Microparticle formulations 
S. No. Ingredients F1 F2 F3 F4 F5 F6 
1 PEG-6000 6 gm 6 gm 6 gm 6 gm 6 gm 6 gm 
2 Diclofenac sodium 50 mg - 50 mg 50 mg - 50 mg 
3 Sulfamethoxazole - 100 mg 100 mg - 100 mg 100 mg 
4 Coconut oil 50 ml 50 ml 50 ml 50 ml 50 ml 50 ml 
5 Span-80 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg 
6 Chitosan - - - 75 mg 75 mg 75 mg 
7 Propylene glycol - - - 0.5 ml 0.5 ml 0.5 ml 
8 N-hexane 50 ml 50 ml 50 ml 50 ml 50 ml 50 ml 
 
Determination of percentage yield: 
The microparticles were dried at room temperature and then it was weighed. 
The percentage yield for the prepared microparticle was calculated using formula81: 
Percentage Yield =  Practical yield x 100 Theoritical yield 
Determination of Drug content: 
Weighed accurately microparticles contain 5 mg of Diclofenac sodium and 10 mg 
Sulfamethoxazole and combination of 5 mg Diclofenac sodium, 10 mg 
Sulfamethoxazole was dissolved in buffer pH 7.4. Then the solution was suitably 
diluted with pH 7.4 and absorbance of the resulting solution was measured at 276 nm 
for diclofenac sodium and 257 nm for sulfamethoxazole in UV double beam 
spectrophotometer against phosphate buffer solution pH 7.4 as blank82 
  Drug content  = Absorbance of  sample x 100 Absorbance of standard 
FT-IR Studies 
  To determine any interaction between drug and polymer, Fourier Transform 
Infra Red (FT-IR) study was carried out. The drug and excipients must be compatible 
with one another to produce a stable, efficacious, easy to administer and safe product. 
FT-IR analysis of pure drug and drug +excipients was studied83. 
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Sieving method procedure: 
 Standard sieve sets of various sizes was selected (sieve no. 10; 22; 36; 44; 65; 
80; 100 & 120). The coarsest sieve (sieve no. 10) is arranged at the top and the finest 
sieve (sieve no.120) was arranged at the bottom. The pan was kept below the sieve 
no.120. A known weight of 10 gm microparticles was weighed and placed on the 
coarsest sieve (sieve no.10). The sieve set was shaken for 15 min. The microparticles 
retained on each sieves was collected separately. Weighed the microparticles retained 
on each sieves84. 
In-Vitro drug release studies: 
In-vitro drug release was studied using USP II apparatus type 1 (basket), with 
900ml of dissolution medium maintained at 37±2°C at 50 rpm by using phosphate 
buffer of pH 7.4 as a dissolution medium. 1ml of sample was withdrawn in different 
time intervals, and the sample was replaced by an equal volume of fresh dissolution 
medium of same pH to maintain the sink condition. The samples were analyzed 
spectrophotometrically at 276 nm Diclofenac sodium and 257 nm for 
Sulfamethoxazole, and the percent drug released was calculated85. 
Gel preparation procedure: 
Weighed accurately (0.5% w/v, 0.75% w/v, 1.00% w/v, 1.25% w/v and 1.5% 
w/v) specific quantity of carbomer. Some amount of distilled water was taken in a 
beaker and to that the weighed amount of carbomer was slowly added (in order to 
prevent the agglomeration of particle) to the beaker containing water. It was mixed 
well with the help of magnetic stirrer at 250 rpm. Care must be taken while mixing to 
prevent the formation of air bubbles in the gel. Mixing was continued until a 
homogeneous mixture was obtained.  Then the volume was make upto 100 ml with 
distilled water and mixed well.  
Gel evaluation procedure: 
Spreadability test: 
1 gm of gel  was weighed and taken in one pre-weighed glass slide to that 
another glass slide was placed over it. The two glass slides were compressed by 
placing a 100 gm weight over it and leave it for 60 sec. for uniform spreading of the 
gel. After 60 sec. the excess gel on the side of the slide was wiped. One glass slide 
was fixed and another one was movable. The movable glass slide was allowed to 
move for a distance of 7.5 cm and the time was noted. Lesser the time taken for the 
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slide to cross the 7.5 cm distance shows better spreadability. The study was performed 
in triplicate86. 
Consistency test: 
Plastic collapsible tubes filled with (0.5% w/v, 0.75% w/v, 1.00% w/v, 1.25% 
w/v and 1.5% w/v) 10 gm of gel. A tube was compressed and extrudibility of the 
formulation was determined in terms of weight in grams applied over the tube. 
Weight required to extrude a 0.5 cm. ribbon of gel in 10 seconds87. 
Microparticles mixed with gel procedure: 
Accurately weighed microparticle (F1, F2, F3, F4, F5 and F6) and 500 mg of 
gel (0.75% w/v and 1.00%w/v) was added slowly in beaker containing magnetic 
stirrer and mixed in magnetic stirrer for 5 min. at 210 rpm.  
Permeation studies procedure: 
A cellophane membrane, (soaked in glycerin 12 hours before use) was fixed to 
one end of the two side open ended cylinder (donor compartment). The sample was 
taken in a cellophane membrane and it was immersed in a beaker containing 100 ml 
of phosphate buffer pH 7.4 (receptor compartment). The entire surface of the 
cellophane membrane was in contact with the receptor compartment which was 
agitated using magnetic stirrer rotated at 200 rpm and a temperature of 37°C±2°C was 
maintained. 1 ml of samples from the receptor compartment was taken at every 5 min. 
interval for 30 min. then 45 and 60 min. and then every 30 min. interval for upto 6 
hrs., same amount of pH 7.4 was replaced. The samples were suitably diluted with pH 
7.4. The absorbance of the resulting solution was then measured at 276 nm for 
Diclofenac sodium and 257 nm for Sulfamethoxazole using UV double beam 
spectrophotometer against phosphate  buffer solution pH 7.4 as blank88. 
Release Kinetics  
To know the release kinetics, the value obtained from in vitro drug release 
studies were plotted in various kinetic models like zero order, first order, higuchi 
model hixson-crowell and korsmeyer–peppas.  
Zero order 
Zero order is Cumulative amount of drug release vs time.  
Equation is C=K0t,  
where  
K0 is the zero order rate constant expressed in units of concentration/time and  
t is the time in hours.  
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First order 
First order is Log cumulative percentage drug remaining vs time.  
Equation is Log C=Log C0–Kt/2.303,  
where  
C0 is the initial concentration of drug,  
K is the first order constant and t is the time.  
Higuchi model 
Higuchi model is the Cumulative percent drug release vs square root of time.  
Equation is Q=Kt1/2,  
where  
K is the constant reflecting the design variables of the system and  
t is the time in hours.  
Hixson-Crowell model 
Hixson-Crowell model is the cube root percent drug remaining vs time.  
Equation is 3√Q0–3√Qt=KHCXt,  
where,  
Q0 is the initial amount of drug in the tablet,  
Qt is the amount of drug release in time t,  
KHC is the ration constant for the Hixson-Crowell rate equation and  
t is the time.  
Korsmeyer–Peppas model  
Korsmeyer peppas is the log cumulative percentage of drug release vs log time.  
The exponent n was calculated through the slope of straight line.  
Mt/M∞=ktn  
Where,  
Mt/M∞ is the fractional solute release,  
K is the kinetic constant characteristic of the drug polymer system,  
t is the release time and  
n is the exponent. 
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RESULTS AND DISCUSSION 
Preformulation studies for pure drug 
Description 
Table-7 
Description of pure Diclofenac sodium 
Properties Specification Observation 
Colour White or slightly yellowish White 
Physical nature Crystalline powder Crystalline powder 
Taste Bitter Bitter 
Odour Odourless Odourless 
 
Corollary: 
 Colour, physical nature, taste and odour of Diclofenac sodium were observed 
and their result in table-7 shows same as the specification. 
Table-8 
Description of pure Sulfamethoxazole 
Properties Specification Observation 
Colour White or almost white White 
Physical Nature Crystalline powder Crystalline powder 
Taste Metallic Metallic 
Odour Unpleasant Unpleasant 
Corollary: 
 Colour, physical nature, taste and odour of Sulfamethoxazole were observed 
and their result shown in table-8 shows same as the specification. 
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Solubility studies 
Table-9 
Solubility analysis of Diclofenac sodium and Sulfamethoxazole 
Solubility Specification/ Observation Diclofenac sodium Sulfamethoxazole 
Water Specification Sparingly soluble Practically insolubleObservation Sparingly soluble Insoluble 
Methanol Specification 
Freely soluble Freely soluble 
Observation Freely soluble Freely soluble 
Ethanol 
(96%) 
Specification Freely soluble Sparingly soluble 
Observation Freely soluble Sparingly soluble 
Acetone Specification 
Slightly soluble Freely soluble 
Observation Slightly soluble Freely soluble 
Corollary: 
Solubility studies of pure Diclofenac sodium and Sulfamethoxazole were 
observed based on the procedure and the reports were shown in table-9. The solubility 
of Diclofenac sodium and Sulfamethoxazole was found to be same as the 
specification. 
Physical properties 
Table-10 
Melting point analysis of Diclofenac sodium and Sulfamethoxazole 
Properties Melting point ranges Observed value 
Diclofenac 
sodium About 280 °C, with decomposition 
Degradation started at 
280°C 
Sulfamethoxazole 169°C to 172°C 169°C 
 
Corollary: 
The observed value for melting point of the both drugs was found to be within 
the range of the monograph and the values are shown in table-10. 
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Table-11 
Physical observation of drug:excipients compatibility studies 
S. No. Drug and excipients Parameter 
1.  Diclofenac sodium No Characteristic change 
2.  Sulfamethoxazole No Characteristic change 
3.  Diclofenac sodium + Sulfamethoxazole No Characteristic change 
4.  Diclofenac sodium + Excipients No Characteristic change 
5.  Sulfamethoxazole + Excipients No Characteristic change 
6.  Diclofenac sodium + Sulfamethoxazole + Excipients No Characteristic change 
Corollary: 
 The drug excipients compatibility from the table-11 showed that there was no 
change or interaction between drug and excipients. Thus it was concluded that the 
excipients selected for the formulation were compatible with pure drug. 
Determination of Percentage Yield: 
The microparticles were dried at room temperature and then it was weighed.  
Table-12 
Percentage yield for the prepared microparticle formulations 
Formulations Percentage yield
F1 95.76 
F2 94.13 
F3 95.12 
F4 96.87 
F5 96.20 
F6 97.18 
Corollary: 
The percentage yield for the prepared microparticle was found to be in the 
range 94.13 to 97.18. The results were tabulated in table-12.  
Determination of Drug content 
The drug content for all the prepared microparticle formulations (F1 to F6) 
were determined by dissolving the microparticle in pH 7.4 and diluted suitably with 
the same solvents. The resulting solution was measured at 276 nm for diclofenac 
RESULTS AND DISCUSSION 
70 
sodium and 257 nm for sulfamethoxazole in UV double beam spectrophotometer 
against phosphate buffer solution pH 7.4 as blank.  
Table-13 
Determination of drug content 
Formulations Drug content 
F1 95.04 
F2 95.52 
F3 Diclo-96.76 Sulfa-96.95 
F4 95.23 
F5 95.55 
F6 96.61 96.88 
Corollary: 
The drug content of diclofenac sodium was found to be in the range of 95.04% 
to 96.76 % and for sulfamethoxazole it was 95.52% to 96.95%. The results were 
shown in table 
FT-IR  Studies 
The FT-IR studies were performed to determine the interaction between drug 
and drug, drug and polymer. The results were shown in table-14 to and figure-5 to 13. 
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Figure-5 
FT-IR for pure Diclofenac sodium     
 
Table-14 
FT-IR for pure Diclofenac sodium 
S. No. Wave number (Cm-1) Functional group 
1.  3163.04 NH stretching of secondary amine 
2.  3121.57 C-H stretching aromatic compound 
3.  1913.25 C=O stretching in ester 
4.  1574.77 C=O stretching carboxyl ion 
5.  1505.34 C=C stretching aromatic compound 
6.  1305.72 C-N stretching group 
7.  1281.61 C-N stretching group 
8.  744.47 C-Cl stretching group 
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Figure-6 
FT-IR for pure Sulfamethoxazole 
 
Table-15 
FT-IR for pure Sulfamethoxazole 
S. No. Wave number (Cm-1) Functional group 
1.  3298.05 NH stretching of group 
2.  3142.79 C-H stretching aromatic group 
3.  2929.67 C-H stretching aliphatic group 
4.  2609.51 C=O stretching carboxyl ion 
5.  1769.57 C-N stretching in oxazole group 
6.  1621.06 C-C stretching group 
7.  1503.41 C=N stretching in oxazole group 
8.  1470.62 C=C stretching aromatic group 
9.  1364.54 S=O stretching group 
10. 1158.17 C-N symmetric SO2 stretching group 
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Figure-7 
FT-IR Combination for Diclofenac sodium and Sulfamethoxazole 
 
Table-16 
FT-IR Combination drug for Diclofenac sodium and Sulfamethoxazole 
S. No. Wave number (Cm-1) Functional group 
1.  3141.82 NH stretching aromatic of group 
2.  1913.25 C=O stretching in ester group 
3.  1574.77 C=O stretching  of carboxylic ion group 
4.  1503.41 C=C stretching aromatic group 
5.  1470.62 C=N stretching in oxazole group  
6.  1365.51 S=O stretching assymetric group 
7.  1307.64 C-N stretching  group 
8.  1158.17 Symmetric SO2 stretching   group 
9.  754.44 C-Cl stretching  Group 
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Figure-8 
FT-IR for F1 formulation 
 
Table-17 
FT-IR for F1 formulation 
S. No.  Wave number (Cm-1)        Functional Group 
1.  3471.87 Amine N-H stretching group. 
2.  2854.65 Alkane C-H stretching group 
3.  1959.68 Aromatic C-H Group 
4.  1743.65 Carboxylic C=O stretching group 
5.  1465.90 Aromatic C-H stretching group 
6.  1111.00 C-O stretching group 
7.  840.96 C-Cl stretching group 
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Figure-9 
FT-IR for F2 formulation 
 
Table-18 
FT-IR for F2 formulation 
 S. No. Wave number (Cm-1) Functional Group 
1.  2885.51 Alkane C-H stretching group 
2.  19759.11 Aromatic C-H Group 
3.  1743.65 Carboxylic C=O stretching group 
4.  1465.90 Aromatic C-H stretching group 
5.  1111.00 C-O stretching group 
6.  840.96 C-Cl stretching group 
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Figure-10 
FT-IR for F3 formulation 
 
Table-19 
FT-IR for F3 formulation 
S. No. Wave number (Cm-1) Functional Group 
1.  2877.79 Alkane C-H stretchin group 
2.  1959.68 Aromatic C-H Group 
3.  1743.65 CarboxylicC=O stretchin group 
4.  1465.90 Aromatic C-H stretching group 
5.  1111.00 C-O stretching group 
6.  840.96 C-Cl stretching group 
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Figure-11 
FT-IR for F4 formulation 
 
Table-20 
FT-IR for F4 formulation 
S. No. Wave number (Cm-1) Functional Group 
1.  3471.87 Amine N-H stretching group. 
2.  2885.51 Alkane C-H stretching group 
3.  1967.39 Aromatic C-H Group 
4.  1743.65 Carboxylic C=O stretching group. 
5.  1465.90 Aromatic C-H stretching group. 
6.  1111.00 C-O stretching group 
7.  840.96 C-Cl stretching group 
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Figure-12 
FT-IR for F5 formulation  
 
Table-21 
FT-IR for F5 formulation 
  S. No.    Wave number (Cm-1)    Functional Group 
1.  2862.36 Alkane C-H stretching group 
2.  1975.11 Aromatic C-H Group 
3.  1743.65 Carboxyli C=O stretching group. 
4.  1465.90 Aromatic C-H stretching group 
5.  1111.00 C-O stretching group 
6.  840.96 C-Cl stretching group 
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Figure-13 
FT-IR for F6 formulation 
 
Table-22 
FT-IR for F6 formulation 
  S.No.  Wave number (Cm-1)        Functional Group 
1.  2885.51 Alkane C-H stretching group 
2.  1975.11 Aromatic C-H Group 
3.  1743.65 CarboxylicC=O stretching group 
4.  1465.90 Aromatic C-H stretching group 
5.  1111.00 C-O stretching group 
6.  840.96 C-Cl stretching group 
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Table-23 
FT – IR Spectrum of pure Diclofenac sodium, Sulfamethoxazole, Combination 
drug Diclofenac sodium + Sulfamethoxazole, F1 formulation, F2 formulation, F3 
formulation, F4 formulation, F5 formulation and F6 formulation 
Functional 
Group 
Amine N-
H 
stretching 
Alkane C-
H 
stretching 
Carboxylic 
C=O 
stretching 
Aromatic 
C-H 
stretching 
C-O 
stretching 
C-Cl 
stretching 
Diclofenac 
Sodium 3385.8 - 1574.77 3121.57 - 744.47 
Sulfamethoxazole 3298.05 - 2609.51 3142.79 1436.87 - 
Diclofenac 
Sodium + 
Sulfamethoxazole 
- - 1574.77 3141.82 1913.25 754.44 
F1 formulation 3471.87 2854.65 1743.65 1465.90 1111.00 840.96 
F2 formulation - 2885.51 1743.65 1465.90 1111.00 840.96 
F3 formulation - 2885.51 1743.65 1465.90 1111.00 840.96 
F4 formulation 3471.87 2885.51 1743.65 1465.90 1111.00 840.96 
F5 formulation 3448.72 2862.36 1743.65 1465.90 1111.00 840.96 
F6 formulation 3448.72 2862.36 1743.65 1465.90 1111.00 840.96 
 
Particle size determination by sieving method 
The size of prepared microparticle formulations (F1 to F6) the size of the 
microparticles were determined by sievieng method. The results were shown in table-
24 to 30 and figure-14 to 19. 
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Table-24 
Particle size of F1 formulations by sieving method 
Sieve 
number 
Aperture sieve 
size as per IP 
specification 
(µm) 
Arithmetic 
mean size of 
opening  
Weight of 
granules 
retained on a 
sieve (over 
size) gm 
% weight of 
granules  
retained 
(under size) 
Cumulative % 
of granules 
retained (under 
size) 
Weight 
size  % 
under 
size  
% 
under 
size  
% over 
size 
(d) µm   (n) (n x d)   
(100 - % 
under 
size) 
10 1700 1205 0 0 0 0 0 0 100 
22 710 922.5 3.51 35.1 35.1 32379.75 32379.8 32.3798 67.6203 
36 425 602.5 2.7 27 62.1 16267.5 48647.3 48.6473 51.3528 
44 355 302.5 2.2 22 84.1 6655 55302.3 55.3023 44.6978 
60 250 215 1.05 10.5 94.6 2257.5 57559.8 57.5598 42.4403 
85 180 165 0.48 4.8 99.4 792 58351.8 58.3518 41.6483 
100 150 137.5 0.06 0.6 100 82.5 58434.3 58.4343 41.5658 
120 125 62.5 0 0 100 0 58434.3 58.4343 41.5658 
Pan 0 0 0 100 0 58434.3 58.4343 41.5658 
   10 ∑n = 100  
∑(nxd) = 
58434.25    
 
RESULTS AND DISCUSSION 
82 
 
Figure-14 
Particle size of F1 formulations by sieving method 
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Table-25 
Particle size of F2 formulations by sieving method 
Sieve 
number 
Aperture 
sieve size as 
per IP 
specification 
(µm) 
Arithmetic 
mean size 
of opening  
Weight of 
granules 
retained 
on a sieve 
(over size) 
gm 
% weight 
of 
granules  
retained 
(under 
size) 
Cumulative 
% of 
granules 
retained 
(under size) 
Weight 
size  % under 
size  
% under 
size  
% over 
size 
(d) µm   (n) (n x d)  
(100 - % 
under 
size) 
10 1700 1205 0 0 0 0 0 0 100 
22 710 922.5 3.425 34.25 34.25 31595.625 31595.625 31.595625 68.404375 
36 425 602.5 2.875 28.75 63 17321.875 48917.5 48.9175 51.0825 
44 355 302.5 2.1 21 84 6352.5 55270 55.27 44.73 
60 250 215 1.025 10.25 94.25 2203.75 57473.75 57.47375 42.52625 
85 180 165 0.475 4.75 99 783.75 58257.5 58.2575 41.7425 
100 150 137.5 0.1 1 100 137.5 58395 58.395 41.605 
120 125 62.5 0 0 100 0 58395 58.395 41.605 
Pan 0 0   0 100 0 58395 58.395 41.605 
      10 ∑n=100  
∑(nxd) 
= 58395       
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Figure-15 
Particle size of F2 formulations by sieving method 
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Table-26 
Particle size of F3 formulations by sieving method 
Sieve 
number 
Aperture sieve 
size as per IP 
specification 
(µm) 
Arithmetic 
mean size of 
opening  
Weight of 
granules 
retained on 
a sieve 
(over size) 
gm 
% weight 
of 
granules  
retained 
(under 
size) 
Cumulative 
% of granules 
retained 
(under size) 
Weight 
size  % under 
size  
% 
under 
size  
% over size 
(d) µm   (n) (n x d)   (100 - % under size) 
10 1700 1205 0 0 0 0 0 0 100 
22 710 922.5 3.63 36.3 36.3 33486.75 33486.8 33.4868 66.5133 
36 425 602.5 2.75 27.5 63.8 16568.75 50055.5 50.0555 49.9445 
44 355 302.5 1.85 18.5 82.3 5596.25 55651.8 55.6518 44.3483 
60 250 215 1.12 11.2 93.5 2408 58059.8 58.0598 41.9403 
85 180 165 0.6 6 99.5 990 59049.8 59.0498 40.9503 
100 150 137.5 0.05 0.5 100 68.75 59118.5 59.1185 40.8815 
120 125 62.5 0 0 100 0       
Pan 0 0   0 100 0       
      10 ∑n=100  
∑(nxd) 
= 59118.5       
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Figure-16 
Particle size of F3 formulations by sieving method 
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Table-27 
Particle size of F4 formulations by sieving method 
Sieve 
number 
Aperture 
sieve size as 
per IP 
specification 
(µm) 
Arithmetic 
mean size 
of opening 
Weight of 
granules 
retained on a 
sieve (over 
size) gm 
% weight 
of granules  
retained 
(under size)
Cumulative % of 
granules 
retained (under 
size) 
Weight 
size  % under 
size  
% under 
size  
% over 
size 
(d) µm   (n) (n x d)   (100 - % under size) 
10 1700 1205 0 0 0 0 0 0 100 
22 710 922.5 5.68 56.76 56.76 52361.1 52361.1 52.3611 47.6389 
36 425 602.5 2.58 25.84 82.6 15568.6 67929.7 67.9297 32.0703 
44 355 302.5 1.29 12.87 95.47 3893.175 71822.875 71.822875 28.177125 
60 250 215 0.33 3.31 98.78 711.65 72534.525 72.534525 27.465475 
85 180 165 0.07 0.72 99.5 118.8 72653.325 72.653325 27.346675 
100 150 137.5 0.05 0.5 100 68.75 72722.075 72.722075 27.277925 
120 125 62.5 0 0 100 0 72722.075 72.722075 27.277925 
Pan 0 0   0 100 0 72722.075 72.722075 27.277925 
      10 ∑n= 100   ∑(nxd) =72722.075       
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Figure-17 
Particle size of F4 formulations by sieving method 
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Table-28 
Particle size of F5 formulations by sieving method 
Sieve 
number 
Aperture sieve 
size as per IP 
specification 
(µm) 
Arithmetic 
mean size of 
opening  
Weight of 
granules 
retained on 
a sieve (over 
size) gm 
% weight 
of granules  
retained 
(under size)
Cumulative % 
of granules 
retained 
(under size) 
Weight 
size  
% under 
size  
 % 
under 
size 
% over 
size 
(d) µm   (n) (n x d)   
(100 - % 
under 
size) 
10 1700 1205 0 0 0 0 0 0 100 
22 710 922.5 5.34 53.4 53.4 49261.5 49261.5 49.2615 50.7385 
36 425 602.5 3.1 31 84.4 18677.5 67939 67.939 32.061 
44 355 302.5 1.21 12.1 96.5 3660.25 71599.25 71.59925 28.40075 
60 250 215 0.26 2.6 99.1 559 72158.25 72.15825 27.84175 
85 180 165 0.09 0.9 100 148.5 72306.75 72.30675 27.69325 
100 150 137.5 0 0 100 0 72306.75 72.30675 27.69325 
120 125 62.5 0 0 100 0 72306.75 72.30675 27.69325 
Pan 0 0   0 100 0 72306.75 72.30675 27.69325 
      10 ∑n= 100   ∑(nxd) =72306.75       
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Figure-18 
Particle size of F5 formulations by sieving method 
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Table-29 
Particle size of F6 formulations by sieving method 
Sieve 
number 
Aperture sieve 
size as per IP 
specification 
(µm) 
Arithmetic 
mean size of 
opening  
Weight of 
granules 
retained on 
a sieve (over 
size) gm 
% weight 
of granules  
retained 
(under size)
Cumulative % 
of granules 
retained 
(under size) 
Weight size  % 
under 
size  
 % 
under 
size 
% over 
size 
(d) µm   (n) (n x d)   
(100 - % 
under 
size) 
10 1700 1205 0 0 0 0 0 0 100 
22 710 922.5 5.95 59.5 59.5 54888.75 54888.8 54.8888 45.1113 
36 425 602.5 2.3 23 82.5 13857.5 68746.3 68.7463 31.2538 
44 355 302.5 1.2 12 94.5 3630 72376.3 72.3763 27.6238 
60 250 215 0.3 3 97.5 645 73021.3 73.0213 26.9788 
85 180 165 0.18 1.8 99.3 297 73318.3 73.3183 26.6818 
100 150 137.5 0.07 3.04348 102.343 418.478261 73736.7 73.7367 26.2633 
120 125 62.5 0 0 102.343 0 73736.7 73.7367 26.2633 
Pan 0 0   0 102.343 0 73736.7 73.7367 26.2633 
      10 ∑n= 100  
∑(nxd) 
=73736.7283       
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Figure-19 
Particle size of F6 formulations by sieving method
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Table-30 
Consolidated data for particle size determinations by sieving method 
Formulations Particle size (µm) 
Without chitosan
F1 584.34 
F2 583.95 
F3 591.19 
With chitosan 
F4 727.22 
F5 723.07 
F6 737.37 
 
Corollary: 
The formulations prepared without chitosan showed the particle size of 584.34 µm for F1 
formulations, 583.95 µm for F2 formulations and 591.19 µm for F3 formulations. The 
formulations prepared with chitosan showed the particle size of 727.22 µm for F4 formulations, 
723.07 µm for F5 formulations and 737.37 µm for F6 formulations. The results of the 
microparticle studies showed the formulations prepared without chitosan had decreased in 
particle size when compared to the formulations prepared with chitosan. 
In-Vitro Drug Release Studies 
The release of pure diclofenac sodium, sulfamethoxazole individually and also by 
combining both drugs and the prepared microparticle formulations were determined in lab India 
disso apparatus at 37±2°C for 30 min. stirring speed of 50 rpm in pH 7.4. The percentage drug 
released at different time intervals were noted and the results were tabulated in table-31 to 46 and 
figure-20 to 23 
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Table-31 
In-Vitro drug release studies of pure Diclofenac sodium 
S. 
No. 
Time 
(min.) 
Absorbance at 276 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.039 0.882352941 7.941176471 15.88235294 
2 10 0.051 1.235294118 11.11764706 22.23529412 
3 15 0.069 1.764705882 15.88235294 31.76470588 
4 20 0.081 2.117647059 19.05882353 38.11764706 
5 25 0.092 2.441176471 21.97058824 43.94117647 
6 30 0.096 2.558823529 23.02941176 46.05882353 
 
Table-32 
In-Vitro drug release studies of pure Sulfamethoxazole 
S. 
No. 
Time 
(min.) 
Absorbance at 257 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.138 2.03125 18.28125 18.28125 
2 10 0.169 2.515625 22.640625 22.640625 
3 15 0.197 2.953125 26.578125 26.578125 
4 20 0.228 3.4375 30.9375 30.9375 
5 25 0.269 4.078125 36.703125 36.703125 
6 30 0.291 4.421875 39.796875 39.796875 
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Table-33 
In-Vitro Drug release studies of pure diclofenac sodium in combination with 
sulfamethoxazole 
S. 
No. 
Time 
(min.) 
Absorbance at 276 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.061 0.935483871 8.419354839 16.83870968 
2 10 0.089 1.387096774 12.48387097 24.96774194 
3 15 0.119 1.870967742 16.83870968 33.67741935 
4 20 0.153 2.419354839 21.77419355 43.5483871 
5 25 0.18 2.85483871 25.69354839 51.38709677 
6 30 0.21 3.338709677 30.0483871 60.09677419 
 
Table-34 
In-Vitro drug release studies of pure sulfamethoxazole  
in combination with diclofenac sodium 
S. 
No. 
Time 
(min.) 
Absorbance at 257 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.313 3.522727273 31.70454545 31.70454545 
2 10 0.389 4.386363636 39.47727273 39.47727273 
3 15 0.412 4.647727273 41.82954545 41.82954545 
4 20 0.476 5.375 48.375 48.375 
5 25 0.512 5.784090909 52.05681818 52.05681818 
6 30 0.581 6.568181818 59.11363636 59.11363636 
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Table-35 
In-Vitro drug release studies of F1 formulation 
S. 
No. 
Time 
(min.) 
Absorbance at 276 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.012 0.088235294 0.794117647 15.88235294 
2 10 0.014 0.147058824 1.323529412 26.47058824 
3 15 0.016 0.205882353 1.852941176 37.05882353 
4 20 0.018 0.264705882 2.382352941 47.64705882 
5 25 0.021 0.352941176 3.176470588 63.52941176 
6 30 0.022 0.382352941 3.441176471 68.82352941 
 
 
Table-36 
In-Vitro drug release studies of F2 formulation 
S. 
No. 
Time 
(min.) 
Absorbance at 257 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.03 0.34375 3.09375 30.9375 
2 10 0.038 0.46875 4.21875 42.1875 
3 15 0.038 0.46875 4.21875 42.1875 
4 20 0.053 0.703125 6.328125 63.28125 
5 25 0.054 0.71875 6.46875 64.6875 
6 30 0.056 0.75 6.75 67.5 
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Table-37 
In-Vitro drug release studies of Diclofenac sodium in F3 formulation 
S. 
No. 
Time 
(min.) 
Absorbance at 276 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.009 0.096774194 0.870967742 17.41935484 
2 10 0.012 0.14516129 1.306451613 26.12903226 
3 15 0.017 0.225806452 2.032258065 40.64516129 
4 20 0.021 0.290322581 2.612903226 52.25806452 
5 25 0.026 0.370967742 3.338709677 66.77419355 
6 30 0.029 0.419354839 3.774193548 75.48387097 
 
 
Table-38 
In-Vitro drug release studies of Sulfamethoxazole in F3 formulation 
S. 
No. 
Time 
(min.) 
Absorbance at 257 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.047 0.5 4.5 45 
2 10 0.052 0.556818182 5.011363636 50.11363636 
3 15 0.058 0.625 5.625 56.25 
4 20 0.059 0.636363636 5.727272727 57.27272727 
5 25 0.074 0.806818182 7.261363636 72.61363636 
6 30 0.083 0.909090909 8.181818182 81.81818182 
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Table-39 
In-Vitro drug release studies of F4 formulation 
S. 
No. 
Time 
(min.) 
Absorbance at 276 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.013 0.117647059 1.058823529 21.17647059 
2 10 0.016 0.205882353 1.852941176 37.05882353 
3 15 0.02 0.323529412 2.911764706 58.23529412 
4 20 0.022 0.382352941 3.441176471 68.82352941 
5 25 0.023 0.411764706 3.705882353 74.11764706 
6 30 0.025 0.470588235 4.235294118 84.70588235 
 
Table-40 
In-Vitro drug release studies of F5 formulation 
S. 
No. 
Time 
(min.) 
Absorbance at 257 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.049 0.640625 5.765625 57.65625 
2 10 0.049 0.640625 5.765625 57.65625 
3 15 0.056 0.75 6.75 67.5 
4 20 0.062 0.84375 7.59375 75.9375 
5 25 0.065 0.890625 8.015625 80.15625 
6 30 0.067 0.921875 8.296875 82.96875 
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Table-41 
In-Vitro drug release studies of Diclofenac sodium in F6 formulation 
S. 
No. 
Time 
(min.) 
Absorbance at 276 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.014 0.177419355 1.596774194 31.9355 
2 10 0.017 0.225806452 2.032258065 40.6452 
3 15 0.021 0.290322581 2.612903226 52.2581 
4 20 0.027 0.387096774 3.483870968 69.6774 
5 25 0.032 0.467741935 4.209677419 84.1935 
6 30 0.037 0.548387097 4.935483871 98.7097 
 
 
 
Table-42 
In-Vitro drug release studies of Sulfamethoxazole in F6 formulation 
S. 
No. 
Time 
(min.) 
Absorbance at 257 
nm 
Concentration 
(µg/ml) 
Drug release 
(mg) 
% Drug 
release 
1 5 0.055 0.590909091 5.318181818 53.18181818 
2 10 0.071 0.772727273 6.954545455 69.54545455 
3 15 0.073 0.795454545 7.159090909 71.59090909 
4 20 0.083 0.909090909 8.181818182 81.81818182 
5 25 0.091 1 9 90 
6 30 0.1 1.102272727 9.920454545 99.20454545 
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Table-43 
Comparison of In-Vitro drug release studies of pure Diclofenac sodium,  
F1 and F4 formulation 
S. No. Time (min.) 
% Drug released 
Pure Diclofenac sodium Formulations  F1 F4 
1 5 15.88 15.88 21.18 
2 10 22.24 26.47 37.06 
3 15 31.76 37.06 58.24 
4 20 38.12 47.65 68.82 
5 25 43.94 63.53 74.12 
6 30 46.06 68.82 84.71 
 
 
 
Figure-20 
Comparison of In-Vitro drug release studies of pure Diclofenac sodium,  
F1 and F4 formulation 
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Table-44 
Comparison of In-Vitro drug release studies of pure Sulfamethoxazole, F2 and F5 
formulation 
S. No. Time (min.) 
% Drug released 
Pure Sulfamethoxazole Formulations  F2 F5 
1 5 18.28 30.94 57.66 
2 10 22.64 42.19 57.66 
3 15 26.58 42.19 67.50 
4 20 30.94 63.28 75.94 
5 25 36.70 64.69 80.16 
6 30 39.80 67.50 82.97 
 
 
Figure-21 
Comparison of In-Vitro drug release studies of pure Sulfamethoxazole, F2 and F5 
formulation 
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Table-45 
Comparison of In-Vitro drug release studies of pure Diclofenac sodium in combination with 
Sulfamethoxazole, F3 and F6 formulation 
S. 
No. 
Time 
(min.) 
% Drug released 
Pure Diclofenac sodium in 
combination with pure 
Sulfamethoxazole 
Diclofenac sodium 
in F3 
Formulations  
Diclofenac sodium 
in F6 
Formulations  
1 5 16.84 17.42 31.94 
2 10 24.97 26.13 40.65 
3 15 33.68 40.65 52.26 
4 20 43.55 52.26 69.68 
5 25 51.39 66.77 84.19 
6 30 60.10 75.48 98.71 
 
 
Figure-22 
Comparison of In-Vitro drug release studies of pure Diclofenac sodium in combination with 
Sulfamethoxazole, F3 and F6 formulation 
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Table-46 
Comparison of In-Vitro drug release studies of pure Sulfamethoxazole in combination with 
Diclofenac sodium, F3 and F6 formulation 
S. 
No. 
Time 
(min.) 
% Drug released 
Pure Sulfamethoxazole in 
combination with pure 
Diclofenac sodium  
Sulfamethoxazole 
in F3 
Formulations  
Sulfamethoxazole 
in F6 
Formulations  
1 5 31.70 45.00 53.18 
2 10 39.48 50.11 69.55 
3 15 41.83 56.25 71.59 
4 20 48.38 57.27 81.82 
5 25 52.06 72.61 90.00 
6 30 59.11 81.82 99.20 
 
 
Figure-23 
Comparison of In-Vitro drug release studies of pure Sulfamethoxazole in combination with 
Diclofenac sodium, F3 and F6 formulation 
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Corollary: 
At 30 min. 46.06% of drug was released in pure Diclofenac sodium, 39.8% of drug was 
released in pure Sulfamethoxazole and 60.10% of Diclofenac sodium was released in 
combination with Sulfamethoxazole, similarly 59.11 % of Sulfamethoxazole was released in 
combination with Diclofenac sodium. The drug release for both the pure drug Diclofenac sodium 
and Sulfamethoxazole in combination showed increased in drug release when compared to 
individual release.  
The Diclofenac sodium prepared without chitosan (F1) showed 68.82% of drug release at 
30 min. The Diclofenac sodium prepared without chitosan (F3) in combination with 
Sulfamethoxazole 75.48% of drug release at 30 min. The Diclofenac sodium prepared with 
chitosan (F4) showed 84.71% of drug release at 30 min. The Diclofenac sodium prepared with 
chitosan (F6) in combination with Sulfamethoxazole showed 98.71% of drug release at 30 min. 
The Sulfamethoxazole prepared without chitosan (F2) showed 67.5% of drug release at 
30 min. The sulfamethoxazole prepared without chitosan (F3) in combination with Diclofenac 
sodium showed 81.82% of drug release at 30 min. The Sulfamethoxazole prepared with chitosan 
(F5) showed 82.97% of drug release at 30 min. The sulfamethoxazole prepared with chitosan 
(F6) in combination with Diclofenac sodium showed 99.21% of drug release at 30 min. 
The drug released study results showed that the release of drugs from microparticles is 
more in formulations containing chitosan. Chitosan may increase the release of the drug. 
Gel evaluation studies: 
 The prepared gels of different concentrations were evaluated for spreadability and 
consistency test.  
Spreadability and consistency test: 
Different concentrations of gel were prepared by carbomer 940. The spreadability and 
consistency test were performed for different gel concentrations (0.05% to 1.25% w/v) to 
determine the spreading tendency and consistency of the gel. The results were shown in               
Table No.47 and 48 
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Table-47 
Spreadability test for different gel concentrations 
Concentrations 
(%w/v) 
M 
(gm) 
L 
(cm) 
T 
(Sec) 
S = 
ML/T Average 
0.50% 
6 7.5 3 15 
15.20±0.07959 6 7.5 2.8 16.07 
6 7.5 3.1 14.52 
0.75% 
6 7.5 7 6.43 
6.59 ±0.1463 6 7.5 6.8 6.62 
6 7.5 6.7 6.72 
1.00% 
6 7.5 11.9 3.78 
3.77±0.0481 6 7.5 11.8 3.81 
6 7.5 12.1 3.72 
1.25% 
6 7.5 16.8 2.68 
2.63±0.0537 6 7.5 17.1 2.63 
6 7.5 17.5 2.57 
1.5% 
6 7.5 25.1 1.79 
1.75±0.0442 6 7.5 26.4 1.7 
6 7.5 25.8 1.74 
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Table-48 
Consistency test for different gel concentrations 
Concentrations 
(%w/v) 
Taken gel (gm) in 
tube 
Applied weight over the 
tube Average 
0.50% 
125 
126.667±1.5275127 
128 
0.75% 
150 150.667±1.1547
 150 
152 
1.00% 
184 184.667±0.5774
 185 
185 
1.25% 
220 221.667±2.8868
 220 225 
1.5% 
295 
295±0 295 
10 295 
 
Gel Permeation Studies 
 Two gel concentrations were selected (0.75%w/v and 1% w/v) based on the results of 
spreadability and consistency test. The microparticles were mixed with 0.75%w/v and 1% w/v 
concentrations and the permeation studies were performed. The results of the permeation studies 
were shown in table-49 to 66 and figure- 24 and 25. 
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Table-49 
Release of F1 formulation microparticles from 0.75 % w/v carbomer (940) gel 
S. 
No. 
Time 
(min.) 
Absorbance 
at 276 nm 
Concentration 
(µg/ml) 
Drug released 
(mg) 
% Drug 
released 
1 5 0.001 0.02941176 0.029411765 0.58823529 
2 10 0.002 0.05882353 0.058823529 1.17647059 
3 15 0.003 0.08823529 0.088235294 1.76470588 
4 20 0.006 0.17647059 0.176470588 3.52941176 
5 25 0.008 0.23529412 0.235294118 4.70588235 
6 30 0.009 0.26470588 0.264705882 5.29411765 
7 45 0.011 0.32352941 0.323529412 6.47058824 
8 60 0.013 0.38235294 0.382352941 7.64705882 
9 90 0.015 0.44117647 0.441176471 8.82352941 
10 120 0.017 0.5 0.5 10 
11 150 0.019 0.55882353 0.558823529 11.1764706 
12 180 0.021 0.61764706 0.617647059 12.3529412 
13 210 0.025 0.73529412 0.735294118 14.7058824 
14 240 0.028 0.82352941 0.823529412 16.4705882 
15 270 0.031 0.91176471 0.911764706 18.2352941 
16 300 0.035 1.02941176 1.029411765 20.5882353 
17 330 0.04 1.17647059 1.176470588 23.5294118 
18 360 0.044 1.29411765 1.294117647 25.8823529 
 
RESULTS AND DISCUSSION 
108 
 
Table-50 
Release of F1 formulation microparticles from 1 % w/v carbomer (940) gel 
S. No.   Time (min.) 
Absorbance 
at 276 nm 
Concentration 
(µg/ml) 
   Drug 
released (mg) 
% Drug 
released 
1 5 0 0 0 0 
2 10 0 0 0 0 
3 15 0.001 0.02941 0.02941 0.58824 
4 20 0.001 0.02941 0.02941 0.58824 
5 25 0.002 0.05882 0.05882 1.17647 
6 30 0.005 0.14706 0.14706 2.94118 
7 45 0.007 0.20588 0.20588 4.11765 
8 60 0.01 0.29412 0.29412 5.88235 
9 90 0.012 0.35294 0.35294 7.05882 
10 120 0.014 0.41176 0.41176 8.23529 
11 150 0.016 0.47059 0.47059 9.41176 
12 180 0.019 0.55882 0.55882 11.1765 
13 210 0.022 0.64706 0.64706 12.9412 
14 240 0.025 0.73529 0.73529 14.7059 
15 270 0.027 0.79412 0.79412 15.8824 
16 300 0.03 0.88235 0.88235 17.6471 
17 330 0.033 0.97059 0.97059 19.4118 
18 360 0.035 1.02941 1.02941 20.5882 
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Table-51 
Release of F2 formulation microparticles from 0.75 % w/v carbomer (940) gel 
S. No.   Time (min.) 
Absorbance 
at 257 nm 
Concentration 
(µg/ml) 
 Drug released 
(mg) 
% Drug 
released 
1 5 0.002 -0.0938 -0.0938 -0.9375 
2 10 0.005 -0.0469 -0.0469 -0.4688 
3 15 0.009 0.01563 0.01563 0.15625 
4 20 0.013 0.07813 0.07813 0.78125 
5 25 0.016 0.125 0.125 1.25 
6 30 0.02 0.1875 0.1875 1.875 
7 45 0.025 0.26563 0.26563 2.65625 
8 60 0.03 0.34375 0.34375 3.4375 
9 90 0.036 0.4375 0.4375 4.375 
10 120 0.041 0.51563 0.51563 5.15625 
11 150 0.046 0.59375 0.59375 5.9375 
12 180 0.052 0.6875 0.6875 6.875 
13 210 0.061 0.82813 0.82813 8.28125 
14 240 0.073 1.01563 1.01563 10.1563 
15 270 0.085 1.20313 1.20313 12.0313 
16 300 0.099 1.42188 1.42188 14.2188 
17 330 0.114 1.65625 1.65625 16.5625 
18 360 0.128 1.875 1.875 18.75 
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Table-52 
Release of F2 formulation microparticles from 1 % w/v carbomer (940) gel 
S. No.   Time (min.) 
Absorbance 
at 257 nm 
Concentration 
(µg/ml) 
Drug released 
(mg) 
% Drug 
released 
1 5 0.001 -0.1094 -0.1094 -1.0938 
2 10 0.003 -0.0781 -0.0781 -0.7813 
3 15 0.006 -0.0313 -0.0313 -0.3125 
4 20 0.01 0.03125 0.03125 0.3125 
5 25 0.013 0.07813 0.07813 0.78125 
6 30 0.017 0.14063 0.14063 1.40625 
7 45 0.02 0.1875 0.1875 1.875 
8 60 0.024 0.25 0.25 2.5 
9 90 0.029 0.32813 0.32813 3.28125 
10 120 0.035 0.42188 0.42188 4.21875 
11 150 0.04 0.5 0.5 5 
12 180 0.046 0.59375 0.59375 5.9375 
13 210 0.053 0.70313 0.70313 7.03125 
14 240 0.062 0.84375 0.84375 8.4375 
15 270 0.07 0.96875 0.96875 9.6875 
16 300 0.079 1.10938 1.10938 11.0938 
17 330 0.091 1.29688 1.29688 12.9688 
18 360 0.102 1.46875 1.46875 14.6875 
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Table-53 
Release of Diclofenac sodium from F3 formulation microparticles from 0.75 % w/v 
carbomer (940) gel 
S. No.   Time (min.) 
Absorbance 
at 276 nm 
Concentration 
(µg/ml) 
Drug released 
(mg) 
% Drug 
released 
1 5 0.003 0.04839 0.04839 0.96774 
2 10 0.005 0.08065 0.08065 1.6129 
3 15 0.01 0.16129 0.16129 3.22581 
4 20 0.013 0.20968 0.20968 4.19355 
5 25 0.016 0.25806 0.25806 5.16129 
6 30 0.018 0.29032 0.29032 5.80645 
7 45 0.021 0.33871 0.33871 6.77419 
8 60 0.025 0.40323 0.40323 8.06452 
9 90 0.029 0.46774 0.46774 9.35484 
10 120 0.033 0.53226 0.53226 10.6452 
11 150 0.04 0.64516 0.64516 12.9032 
12 180 0.047 0.75806 0.75806 15.1613 
13 210 0.054 0.87097 0.87097 17.4194 
14 240 0.06 0.96774 0.96774 19.3548 
15 270 0.071 1.14516 1.14516 22.9032 
16 300 0.077 1.24194 1.24194 24.8387 
17 330 0.085 1.37097 1.37097 27.4194 
18 360 0.092 1.48387 1.48387 29.6774 
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Table-54 
Release of Sulfamethoxazole from F3 formulation microparticles from 0.75 % w/v 
carbomer (940) gel 
S. No.   Time (min.) 
Absorbance 
at 257 nm 
Concentration 
(µg/ml) 
Drug 
released (mg) 
% Drug 
released 
1 5 0.003 0 0 0 
2 10 0.006 0.05551 0.05551 0.55507 
3 15 0.008 0.08368 0.08368 0.83676 
4 20 0.012 0.14001 0.14001 1.40014 
5 25 0.016 0.19635 0.19635 1.96352 
6 30 0.02 0.25269 0.25269 2.5269 
7 45 0.024 0.30903 0.30903 3.09028 
8 60 0.029 0.37945 0.37945 3.79451 
9 90 0.038 0.50621 0.50621 5.06211 
10 120 0.049 0.66114 0.66114 6.61141 
11 150 0.057 0.77382 0.77382 7.73817 
12 180 0.066 0.90058 0.90058 9.00577 
13 210 0.078 1.06959 1.06959 10.6959 
14 240 0.091 1.25269 1.25269 12.5269 
15 270 0.102 1.40762 1.40762 14.0762 
16 300 0.122 1.68931 1.68931 16.8931 
17 330 0.142 1.971 1.971 19.71 
18 360 0.16 2.22452 2.22452 22.2452 
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Table-55 
Release of Diclofenac sodium from F3 formulation microparticles from 1 % w/v carbomer 
(940) gel 
S. No.   Time (min.) 
Absorbance 
at 276 nm 
Concentration 
(µg/ml) 
  Drug released 
(mg) 
% Drug 
released 
1 5 0.001 0.01613 0.01613 0.32258 
2 10 0.003 0.04839 0.04839 0.96774 
3 15 0.008 0.12903 0.12903 2.58065 
4 20 0.01 0.16129 0.16129 3.22581 
5 25 0.012 0.19355 0.19355 3.87097 
6 30 0.015 0.24194 0.24194 4.83871 
7 45 0.018 0.29032 0.29032 5.80645 
8 60 0.02 0.32258 0.32258 6.45161 
9 90 0.023 0.37097 0.37097 7.41935 
10 120 0.028 0.45161 0.45161 9.03226 
11 150 0.034 0.54839 0.54839 10.9677 
12 180 0.038 0.6129 0.6129 12.2581 
13 210 0.046 0.74194 0.74194 14.8387 
14 240 0.053 0.85484 0.85484 17.0968 
15 270 0.059 0.95161 0.95161 19.0323 
16 300 0.065 1.04839 1.04839 20.9677 
17 330 0.069 1.1129 1.1129 22.2581 
18 360 0.08 1.29032 1.29032 25.8065 
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Table-56 
Release of Sulfamethoxazole from F3 formulation microparticles from 1 % w/v carbomer 
(940) gel 
S. No.   Time (min.) 
Absorbance 
at 257 nm 
Concentration 
(µg/ml) 
Drug released 
(mg) 
% Drug 
released 
1 5 0 -0.0341 -0.0341 -0.3409 
2 10 0.001 -0.0227 -0.0227 -0.2273 
3 15 0.004 0.01136 0.01136 0.11364 
4 20 0.007 0.04545 0.04545 0.45455 
5 25 0.01 0.07955 0.07955 0.79545 
6 30 0.014 0.125 0.125 1.25 
7 45 0.023 0.22727 0.22727 2.27273 
8 60 0.032 0.32955 0.32955 3.29545 
9 90 0.044 0.46591 0.46591 4.65909 
10 120 0.055 0.59091 0.59091 5.90909 
11 150 0.063 0.68182 0.68182 6.81818 
12 180 0.072 0.78409 0.78409 7.84091 
13 210 0.084 0.92045 0.92045 9.20455 
14 240 0.095 1.04545 1.04545 10.4545 
15 270 0.108 1.19318 1.19318 11.9318 
16 300 0.123 1.36364 1.36364 13.6364 
17 330 0.136 1.51136 1.51136 15.1136 
18 360 0.158 1.76136 1.76136 17.6136 
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Table-57 
Release of F4 formulation microparticles from 0.75 % w/v carbomer (940) gel 
S. 
No.  
 Time 
(min.) 
Absorbance 
at 276 nm 
Concentration 
(µg/ml) 
Drug 
released (mg)
% Drug 
released 
1 5 0.002 0.05882353 0.058823529 1.176470588 
2 10 0.003 0.08823529 0.088235294 1.764705882 
3 15 0.006 0.17647059 0.176470588 3.529411765 
4 20 0.008 0.23529412 0.235294118 4.705882353 
5 25 0.01 0.29411765 0.294117647 5.882352941 
6 30 0.011 0.32352941 0.323529412 6.470588235 
7 45 0.013 0.38235294 0.382352941 7.647058824 
8 60 0.015 0.44117647 0.441176471 8.823529412 
9 90 0.018 0.52941176 0.529411765 10.58823529 
10 120 0.021 0.61764706 0.617647059 12.35294118 
11 150 0.025 0.73529412 0.735294118 14.70588235 
12 180 0.03 0.88235294 0.882352941 17.64705882 
13 210 0.033 0.97058824 0.970588235 19.41176471 
14 240 0.037 1.08823529 1.088235294 21.76470588 
15 270 0.04 1.17647059 1.176470588 23.52941176 
16 300 0.044 1.29411765 1.294117647 25.88235294 
17 330 0.049 1.44117647 1.441176471 28.82352941 
18 360 0.052 1.52941176 1.529411765 30.58823529 
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Table-58 
Release of F4 formulation microparticles from 1 % w/v carbomer (940) gel 
S. 
No.  
 Time 
(min.) 
Absorbance at 
276 nm 
Concentration 
(µg/ml) 
Drug released 
(mg) 
% Drug 
released 
1 5 0 0 0 0 
2 10 0.001 0.02941 0.02941 0.58824 
3 15 0.002 0.05882 0.05882 1.17647 
4 20 0.004 0.11765 0.11765 2.35294 
5 25 0.006 0.17647 0.17647 3.52941 
6 30 0.009 0.26471 0.26471 5.29412 
7 45 0.011 0.32353 0.32353 6.47059 
8 60 0.013 0.38235 0.38235 7.64706 
9 90 0.015 0.44118 0.44118 8.82353 
10 120 0.018 0.52941 0.52941 10.5882 
11 150 0.021 0.61765 0.61765 12.3529 
12 180 0.024 0.70588 0.70588 14.1176 
13 210 0.029 0.85294 0.85294 17.0588 
14 240 0.032 0.94118 0.94118 18.8235 
15 270 0.035 1.02941 1.02941 20.5882 
16 300 0.038 1.11765 1.11765 22.3529 
17 330 0.041 1.20588 1.20588 24.1176 
18 360 0.045 1.32353 1.32353 26.4706 
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Table-59 
Release of F5 formulation microparticles from 0.75 % w/v carbomer (940) gel 
S. 
No.  
 Time 
(min.) 
Absorbance 
at 257 nm 
Concentration 
(µg/ml) 
Drug released 
(mg) 
% Drug 
released 
1 5 0.01 0.03125 0.03125 0.3125 
2 10 0.014 0.09375 0.09375 0.9375 
3 15 0.018 0.15625 0.15625 1.5625 
4 20 0.02 0.1875 0.1875 1.875 
5 25 0.022 0.21875 0.21875 2.1875 
6 30 0.025 0.265625 0.265625 2.65625 
7 45 0.029 0.328125 0.328125 3.28125 
8 60 0.035 0.421875 0.421875 4.21875 
9 90 0.044 0.5625 0.5625 5.625 
10 120 0.05 0.65625 0.65625 6.5625 
11 150 0.058 0.78125 0.78125 7.8125 
12 180 0.066 0.90625 0.90625 9.0625 
13 210 0.078 1.09375 1.09375 10.9375 
14 240 0.088 1.25 1.25 12.5 
15 270 0.1 1.4375 1.4375 14.375 
16 300 0.109 1.578125 1.578125 15.78125 
17 330 0.123 1.796875 1.796875 17.96875 
18 360 0.135 1.984375 1.984375 19.84375 
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Table-60 
Release of F5 formulation microparticles from 1 % w/v carbomer (940) gel 
S. 
No.  
 Time 
(min.) 
Absorbance 
at 257 nm 
Concentration 
(µg/ml) 
Drug released 
(mg) 
% Drug 
released 
1 5 0.005 -0.0469 -0.0469 -0.4688 
2 10 0.008 0 0 0 
3 15 0.011 0.04688 0.04688 0.46875 
4 20 0.015 0.10938 0.10938 1.09375 
5 25 0.018 0.15625 0.15625 1.5625 
6 30 0.021 0.20313 0.20313 2.03125 
7 45 0.026 0.28125 0.28125 2.8125 
8 60 0.031 0.35938 0.35938 3.59375 
9 90 0.035 0.42188 0.42188 4.21875 
10 120 0.039 0.48438 0.48438 4.84375 
11 150 0.045 0.57813 0.57813 5.78125 
12 180 0.052 0.6875 0.6875 6.875 
13 210 0.061 0.82813 0.82813 8.28125 
14 240 0.067 0.92188 0.92188 9.21875 
15 270 0.077 1.07813 1.07813 10.7813 
16 300 0.091 1.29688 1.29688 12.9688 
17 330 0.103 1.48438 1.48438 14.8438 
18 360 0.114 1.65625 1.65625 16.5625 
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Table-61 
Release of Diclofenac sodium from F6 formulation microparticles from 0.75 % w/v 
carbomer (940) gel 
S. 
No.  
 Time 
(min.) 
Absorbance 
at 276 nm 
Concentration 
(µg/ml) 
   Drug released 
(mg) 
% Drug 
released 
1 5 0.009 0.09677 0.09677 1.93548 
2 10 0.012 0.14516 0.14516 2.90323 
3 15 0.016 0.20968 0.20968 4.19355 
4 20 0.019 0.25806 0.25806 5.16129 
5 25 0.022 0.30645 0.30645 6.12903 
6 30 0.025 0.35484 0.35484 7.09677 
7 45 0.03 0.43548 0.43548 8.70968 
8 60 0.036 0.53226 0.53226 10.6452 
9 90 0.04 0.59677 0.59677 11.9355 
10 120 0.047 0.70968 0.70968 14.1935 
11 150 0.055 0.83871 0.83871 16.7742 
12 180 0.064 0.98387 0.98387 19.6774 
13 210 0.07 1.08065 1.08065 21.6129 
14 240 0.079 1.22581 1.22581 24.5161 
15 270 0.086 1.33871 1.33871 26.7742 
16 300 0.093 1.45161 1.45161 29.0323 
17 330 0.101 1.58065 1.58065 31.6129 
18 360 0.108 1.69355 1.69355 33.871 
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Table-62 
Release of Sulfamethoxazole from F6 formulation microparticles from 0.75 % w/v 
carbomer (940) gel 
S. 
No.  
 Time 
(min.) 
Absorbance 
at 257 nm 
Concentration 
(µg/ml) 
Drug released 
(mg) 
% Drug 
released 
1 5 0.008 0.056818182 0.0568182 0.568181818 
2 10 0.013 0.113636364 0.1136364 1.136363636 
3 15 0.019 0.181818182 0.1818182 1.818181818 
4 20 0.022 0.215909091 0.2159091 2.159090909 
5 25 0.026 0.261363636 0.2613636 2.613636364 
6 30 0.031 0.318181818 0.3181818 3.181818182 
7 45 0.039 0.409090909 0.4090909 4.090909091 
8 60 0.048 0.511363636 0.5113636 5.113636364 
9 90 0.059 0.636363636 0.6363636 6.363636364 
10 120 0.071 0.772727273 0.7727273 7.727272727 
11 150 0.082 0.897727273 0.8977273 8.977272727 
12 180 0.096 1.056818182 1.0568182 10.56818182 
13 210 0.112 1.238636364 1.2386364 12.38636364 
14 240 0.136 1.511363636 1.5113636 15.11363636 
15 270 0.169 1.886363636 1.8863636 18.86363636 
16 300 0.186 2.079545455 2.0795455 20.79545455 
17 330 0.198 2.215909091 2.2159091 22.15909091 
18 360 0.221 2.477272727 2.4772727 24.77272727 
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Table-63 
Release of Diclofenac sodium from F6 formulation microparticles from 1 % w/v carbomer 
(940) gel 
S. No.   Time (min.) 
Absorbance 
at 276 nm 
Concentration 
(µg/ml) 
Drug released 
(mg) 
% Drug 
released 
1 5 0.005 0.03226 0.03226 0.64516 
2 10 0.008 0.08065 0.08065 1.6129 
3 15 0.011 0.12903 0.12903 2.58065 
4 20 0.016 0.20968 0.20968 4.19355 
5 25 0.02 0.27419 0.27419 5.48387 
6 30 0.023 0.32258 0.32258 6.45161 
7 45 0.027 0.3871 0.3871 7.74194 
8 60 0.031 0.45161 0.45161 9.03226 
9 90 0.036 0.53226 0.53226 10.6452 
10 120 0.041 0.6129 0.6129 12.2581 
11 150 0.044 0.66129 0.66129 13.2258 
12 180 0.054 0.82258 0.82258 16.4516 
13 210 0.061 0.93548 0.93548 18.7097 
14 240 0.071 1.09677 1.09677 21.9355 
15 270 0.077 1.19355 1.19355 23.871 
16 300 0.082 1.27419 1.27419 25.4839 
17 330 0.088 1.37097 1.37097 27.4194 
18 360 0.095 1.48387 1.48387 29.6774 
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Table-64 
Release of Sulfamethoxazole from F6 formulation microparticles from 1 % w/v carbomer 
(940) gel 
S. 
No.  
 Time 
(min.) 
Absorbance 
at 257 nm 
Concentration 
(µg/ml) 
   Drug released 
(mg) 
% Drug 
released 
1 5 0.006 0.034 0.03409 0.34091 
2 10 0.009 0.068 0.06818 0.68182 
3 15 0.013 0.114 0.11364 1.13636 
4 20 0.018 0.17 0.17045 1.70455 
5 25 0.021 0.205 0.20455 2.04545 
6 30 0.025 0.25 0.25 2.5 
7 45 0.032 0.33 0.32955 3.29545 
8 60 0.041 0.432 0.43182 4.31818 
9 90 0.05 0.534 0.53409 5.34091 
10 120 0.061 0.659 0.65909 6.59091 
11 150 0.07 0.761 0.76136 7.61364 
12 180 0.083 0.909 0.90909 9.09091 
13 210 0.095 1.045 1.04545 10.4545 
14 240 0.109 1.205 1.20455 12.0455 
15 270 0.127 1.409 1.40909 14.0909 
16 300 0.144 1.602 1.60227 16.0227 
17 330 0.162 1.807 1.80682 18.0682 
18 360 0.189 2.114 2.11364 21.1364 
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Table-65 
Comparison of Diclofenac sodium microparticles released from two different gel 
formulations (0.75% and 1% w/v) 
S. 
No.  
Time 
(min.) 
Percentage drug released 
F1 (Diclo 
without chito) 
F3 (Diclo without 
chito in combi) 
F4 (Diclo with 
chito) 
F6 (Diclo with 
chito in combi) 
0.75% 1% 0.75% 1% 0.75% 1% 0.75% 1% 
1 5 0.59 0.00 0.97 0.32 1.18 0.00 1.94 0.65 
2 10 1.18 0.00 1.61 0.97 1.76 0.59 2.90 1.61 
3 15 1.76 0.59 3.23 2.58 3.53 1.18 4.19 2.58 
4 20 3.53 0.59 4.19 3.23 4.71 2.35 5.16 4.19 
5 25 4.71 1.18 5.16 3.87 5.88 3.53 6.13 5.48 
6 30 5.29 2.94 5.81 4.84 6.47 5.29 7.10 6.45 
7 45 6.47 4.12 6.77 5.81 7.65 6.47 8.71 7.74 
8 60 7.65 5.88 8.06 6.45 8.82 7.65 10.65 9.03 
9 90 8.82 7.06 9.35 7.42 10.59 8.82 11.94 10.65 
10 120 10.00 8.24 10.65 9.03 12.35 10.59 14.19 12.26 
11 150 11.18 9.41 12.90 10.97 14.71 12.35 16.77 13.23 
12 180 12.35 11.18 15.16 12.26 17.65 14.12 19.68 16.45 
13 210 14.71 12.94 17.42 14.84 19.41 17.06 21.61 18.71 
14 240 16.47 14.71 19.35 17.10 21.76 18.82 24.52 21.94 
15 270 18.24 15.88 22.90 19.03 23.53 20.59 26.77 23.87 
16 300 20.59 17.65 24.84 20.97 25.88 22.35 29.03 25.48 
17 330 23.53 19.41 27.42 22.26 28.82 24.12 31.61 27.42 
18 360 25.88 20.59 29.68 25.81 30.59 26.47 33.87 29.68 
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Graph-24 
Comparison of Diclofenac sodium microparticles released from two different gel 
formulations (0.75% and 1% w/v) 
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Table-66 
Comparison of Sulfamethoxazole microparticles released from two different gel 
formulations (0.75% and 1% w/v) 
S. 
No 
Time 
(min.) 
Percentage drug released 
F2 (Sulfa 
without chito) 
F3 (Sulfa 
without chito in 
combi) 
F5 (Sulfa with 
chito) 
F6 (Sulfa with chito 
in combi) 
F2 
(0.75%) 
F2 
(1%) 
F3 
(0.75%) 
F3 
(1%) 
F5 
(0.75%) 
F5 
(1%) 
F6 
(0.75%) F6 (1%) 
1 5 0.00 0.00 0.00 0.00 0.31 0.00 0.57 0.34 
2 10 0.00 0.00 0.56 0.00 0.94 0.00 1.14 0.68 
3 15 0.16 0.00 0.84 0.11 1.56 0.47 1.82 1.14 
4 20 0.78 0.31 1.40 0.45 1.88 1.09 2.16 1.70 
5 25 1.25 0.78 1.96 0.80 2.19 1.56 2.61 2.05 
6 30 1.88 1.41 2.53 1.25 2.66 2.03 3.18 2.50 
7 45 2.66 1.88 3.09 2.27 3.28 2.81 4.09 3.30 
8 60 3.44 2.50 3.79 3.30 4.22 3.59 5.11 4.32 
9 90 4.38 3.28 5.06 4.66 5.63 4.22 6.36 5.34 
10 120 5.16 4.22 6.61 5.91 6.56 4.84 7.73 6.59 
11 150 5.94 5.00 7.74 6.82 7.81 5.78 8.98 7.61 
12 180 6.88 5.94 9.01 7.84 9.06 6.88 10.57 9.09 
13 210 8.28 7.03 10.70 9.20 10.94 8.28 12.39 10.45 
14 240 10.16 8.44 12.53 10.45 12.50 9.22 15.11 12.05 
15 270 12.03 9.69 14.08 11.93 14.38 10.78 18.86 14.09 
16 300 14.22 11.09 16.89 13.64 15.78 12.97 20.80 16.02 
17 330 16.56 12.97 19.71 15.11 17.97 14.84 22.16 18.07 
18 360 18.75 14.69 22.25 17.61 19.84 16.56 24.77 21.14 
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Graph-25 
Comparison of Sulfamethoxazole microparticles released from two different gel 
formulations (0.75% and 1% w/v) 
Corollary: 
F1 formulation in 0.75 % w/v carbomer (940) gel 25.88 % of drug was released for a 
period of 6 hrs. F1 formulation in 1 % w/v carbomer (940) gel 20.59 % of drug was released for 
a period of 6 hrs. F2 formulation in 0.75 % w/v carbomer (940) gel 18.75 % of drug was released 
for a period of 6 hrs. F2 formulation in 1 % w/v carbomer (940) gel 14.69 % of drug was 
released for a period of 6 hrs. Release of Diclofenac sodium from F3 formulation in 0.75 % w/v 
carbomer (940) gel 29.68 % of drug was released for a period of 6 hrs. Release of 
Sulfamethoxazole from F3 formulation in 0.75 % w/v carbomer (940) gel 22.25 % of drug was 
released for a period of 6 hrs. Release of Diclofenac sodium from F3 formulation in 1 % w/v 
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carbomer (940) gel 25.81 % of drug was released for a period of 6 hrs. Release of 
Sulfamethoxazole from F3 formulation in 1 % w/v carbomer (940) gel 17.61% of drug was 
released for a period of 6 hrs. F4 formulation in 0.75 % w/v carbomer (940) gel 30.59 % of drug 
was released for a period of 6 hrs. F4 formulation in 1 % w/v carbomer (940) gel 26.47 % of 
drug was released for a period of 6 hrs. F5 formulation in 0.75 % w/v carbomer (940) gel 19.84 
% of drug was released for a period of 6 hrs. F5 formulation in 1 % w/v carbomer (940) gel 
16.56 % of drug was released for a period of 6 hrs. Release of Diclofenac sodium from F6 
formulation in 0.75 % w/v carbomer (940) gel 33.87 % of drug was released for a period of 6 
hrs. Release of Sulfamethoxazole from F3 formulation in 0.75 % w/v carbomer (940) gel 24.77 
% of drug was released for a period of 6 hrs. Release of Diclofenac sodium from F6 formulation 
in 1 % w/v carbomer (940) gel 29.68 % of drug was released for a period of 6 hrs. Release of 
Sulfamethoxazole from F3 formulation in 1 % w/v carbomer (940) gel 21.13 % of drug was 
released for a period of 6 hrs. 
Release Kinetics 
The drug released data was fitted to various release kinetics. The formulation follows 
zero order kinetics. The results were shown in table-67 
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Table-67 
Drug release kinetics of microparticles formulations 
Formulations Concentrations (%w/v) 
Zero 
order 
First 
order Higuchi Hixson 
Korsme
yer-
Peppas 
n value 
F1 (Diclo 
without chito 
0.75% 0.978 0.978 0.96 0.978 0.954 y = 0.777x - 0.588 
1% 0.985 0.989 0.984 0.989 0.902 y = 0.898x - 0.978 
F2 (Sulfa 
without chito  
0.75% 0.977 0.97 0.919 0.974 0.83 y = 0.876x - 1.08 
1% 0.988 0.985 0.938 0.987 0.846 y = 0.781x - 0.964 
F3 (Diclo 
without chito in 
combi)  
0.75% 0.99 0.988 0.961 0.988 0.975 y = 0.722x - 0.404 
1% 0.989 0.987 0.962 0.988 0.937 y = 0.839x - 0.736 
F3 (Sulfa 
without chito in 
combi) 
0.75% 0.985 0.977 0.929 0.981 0.954 y = 0.842x - 0.902 
1% 0.993 0.992 0.961 0.993 0.802 y = 0.955x - 1.265 
F4 (Diclo with 
chito) 
0.75% 0.989 0.993 0.979 0.99 0.977 y = 0.704x - 0.326 
1% 0.0983 0.989 0.984 0.987 0.941 y = 0.854x - 0.742 
F5 (Sulfa with 
chito) 
0.75% 0.994 0.991 0.954 0.993 0.982 y = 0.848x - 0.902 
1% 0.982 0.977 0.935 0.98 0.918 y = 0.767x - 0.847 
F6 (Diclo with 
chito in combi) 
0.75% 0.991 0.995 0.982 0.991 0.994 y = 0.645x - 0.145 
1% 0.984 0.989 0.978 0.986 0.959 y = 0.778x - 0.497 
F6 (Sulfa with 
chito in combi) 
0.75% 0.988 0.981 0.934 0.985 0.99 y = 0.820x - 0.759 
1% 0.988 0.982 0.94 0.985 0.989 y = 0.886x - 0.993 
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CONCLUSION 
 
The presence of more than one API in single-unit dosage form such as tablet is 
common practice and even had the market success. However, development of 
multiple-unit dosage form such as microparticles with more than one API is not a 
common practice and none of the microparticles entered so far into market using the 
concept of dual drug loading. In this work, the two drugs namely, Diclofenac sodium 
and Sulfamethoxazole were encapsulated into microparticles formulation prepared by 
cold/hot-dispersion method. But after the microparticles formation, the current pilot 
experimental studies using IR spectroscopy, UV-analysis, TLC, etc. indicated that 
both of these two APIs underwent interaction within the microparticles itself. Thus 
further experimental studies should be needed to confirm the fact that whether or not 
the predicted interaction between these two drugs occurred at molecular (solid 
solution) level inside the hydrophilic polymer-based microparticles.     
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